

Set Items Description

? e au=fischer, gerald

Ref	Items	Index-term
E1	1	AU=FI SCHER, GEORGE W
E2	5	AU=FI SCHER, GEORGES
E3	54	AU=FI SCHER, GERALD
E4	1	AU=FI SCHER, GERALD CHARLES
E5	3	AU=FI SCHER, GERALD W
E6	27	AU=FI SCHER, GERALD W
E7	5	AU=FI SCHER, GERALD WALTER
E8	2	AU=FI SCHER, GERALD
E9	105	AU=FI SCHER, GERD
E10	3	AU=FI SCHER, GERD M
E11	9	AU=FI SCHER, GERD M
E12	1	AU=FI SCHER, GERD.
E13	17	AU=FI SCHER, GERDA
E14	261	AU=FI SCHER, GERHARD
E15	2	AU=FI SCHER, GERHARD E.
E16	9	AU=FI SCHER, GERHARD EM L
E17	12	AU=FI SCHER, GERHARD G
E18	2	AU=FI SCHER, GERHARD H
E19	1	AU=FI SCHER, GERHARD H.
E20	3	AU=FI SCHER, GERHARD L.
E21	1	AU=FI SCHER, GERHARD RI CHARD
E22	1	AU=FI SCHER, GERHARD V.
E23	142	AU=FI SCHER, GERHARD W
E24	1	AU=FI SCHER, GERHARDT
E25	12	AU=FI SCHER, GERNOT

Enter P or PAGE for more

? s e1-e25

1	AU=FI SCHER, GEORGE W
5	AU=FI SCHER, GEORGES
54	AU=FI SCHER, GERALD
1	AU=FI SCHER, GERALD CHARLES
3	AU=FI SCHER, GERALD W
27	AU=FI SCHER, GERALD W
5	AU=FI SCHER, GERALD WALTER
2	AU=FI SCHER, GERALD
105	AU=FI SCHER, GERD
3	AU=FI SCHER, GERD M
9	AU=FI SCHER, GERD M
1	AU=FI SCHER, GERD.
17	AU=FI SCHER, GERDA
261	AU=FI SCHER, GERHARD
2	AU=FI SCHER, GERHARD E.
9	AU=FI SCHER, GERHARD EM L
12	AU=FI SCHER, GERHARD G
2	AU=FI SCHER, GERHARD H
1	AU=FI SCHER, GERHARD H.
3	AU=FI SCHER, GERHARD L.
1	AU=FI SCHER, GERHARD RI CHARD
1	AU=FI SCHER, GERHARD V.
142	AU=FI SCHER, GERHARD W
1	AU=FI SCHER, GERHARDT
12	AU=FI SCHER, GERNOT

S1 680 E1-E25

? s1 and staphylococcus

Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing

Processing
Processing
Processed 10 of 39 files ...
Processing
Processing
Processing
Processed 20 of 39 files ...
Processing
Processed 30 of 39 files ...
Completed processing all files
52154472 1
933353 STAPHYLOCOCCUS
S2 287001 1 AND STAPHYLOCOCCUS

? s s2 and monoclonal

287001 S2
1716994 MONOCLONAL
S3 4365 S2 AND MONOCLONAL

? s s3 and tei choi c

4365 S3
13931 TEI CHOI C
S4 45 S3 AND TEI CHOI C

? rd

S5 25 RD (unique items)

? t s5/3, k/1-25

>>> KWC option is not available in file(s): 399
Dialog eLink:

5/3, K/1 (Item 1 from file: 24)
 Dialog File 24: CSA Life Sciences Abstracts
 (c) 2012 CSA. All rights reserved.

0001459292 IP Accession No: 3700940
 Gram-positive cell walls stimulate synthesis of tumor necrosis factor alpha and interleukin-6 by human monocytes

Heumann, D; Barras, C; Severin, A; Gauser, MP; Tomasz, A Lab. Microbiol.,
 Rockefeller Univ., 1230 York Ave., New York, NY 10021, USA
 Infection and Immunity, v 62, n 7, p 2715-2721, 1994
 Addl. Source Info: Infection and Immunity [INFECT. IMMUN.], vol. 62, no. 7, pp.
 2715-2721, 1994
 Publication Date: 1994

Document Type: Journal Article
 Record Type: Abstract
 Language: English
 Summary Language: English
 ISSN: 0019-9567
 File Segment: Bacteriology Abstracts (Microbiology B); Immunology Abstracts

Abstract:
 Purified cell walls representing a wide variety in teichoic acid and peptidoglycan structure prepared from eight different gram-positive bacterial species induced the production... serum Significant amounts of cytokines began to be produced at concentrations above 100 ng to 1 mu g of cell walls per ml, with maximal production requiring 10 to 100 mu... normal with hypogammaglobulinemic plasma, inactivation of complement (at 56 degree C), and blockade by the monoclonal antibody MY4 of the CD14 receptors on monocytes did not inhibit the production of TNF... also produced this cytokine when stimulated by cell walls. Both peptidoglycan and the soluble glycan-teichoic acid component prepared by an enzymatic method from the same wall preparation exhibited a serum..

Descriptors: cell walls; activation; monocytes; biosynthesis; interleukin 6; man; Staphylococcus epidermidis; Staphylococcus aureus
 Identifiers:

Dialog eLink:
 5/3, K/2 (Item 2 from file: 24)
 Dialog File 24: CSA Life Sciences Abstracts
 (c) 2012 CSA. All rights reserved.

0000483734 IP Accession No: 1331474
 Antibodies to lipoteichoic acid from Staphylococcus aureus: Specificity of murine monoclonal and human antibodies.

Aasjord, P; Haheim LR Per Aasjord Avd. Microbiol. og Immunol., Gades Inst., Univ. Bergen, MFH-bygget, N-5016 Haukeland Sykehus, Norway
 ACTA PATHOL., MICROBIOL. IMMUNOL. SCAND., SECT. C., v 93, n 6, p 245-250, 1985
 Addl. Source Info: ACTA PATHOL., MICROBIOL. IMMUNOL. SCAND., SECT. C., vol. 93, no. 6, pp. 245-250, 1985
 Publication Date: 1985

Document Type: Journal Article
 Record Type: Abstract
 Language: English
 Summary Language: English

10601171

File Segment: Bacteriology Abstracts (Microbiology B); Immunology Abstracts
Antibodies to lipoteichoic acid from Staphylococcus aureus : Specificity of murine
monoclonal and human antibodies.

Abstract:

Two monoclonal antibodies against staphylococcal lipoteichoic acid (LTA) were made by fusing P3X63Ag8 myeloma cells and splenocytes... .mixture of LTA. In contrast, CSF antibodies from 6 of the 7 MS patients and 1 of the 7 non-MS patients had affinity for the alanine residue. This non-MS...

Descriptors: monoclonal antibodies; Staphylococcus aureus

Identifiers: immunodiagnosis; man; teichoic acid

Dialog eLink:

5/3, K/3 (Item 1 from file: 34)

DIALOG(R) File 34: SciSearch(R) Cited Ref Sci

(c) 2012 The Thomson Corp. All rights reserved.

23410144 Genuine Article#: 90600 No. References: 48

Title: Protection Against Staphylococcus aureus by Antibody to the

Polyglycerol phosphate Backbone of Heterologous Lipoteichoic Acid

Author: Theilacker C (REPRINT) ; Kropec A; Hammer F; Sava I; Wöbser D; Sakinc T;

Codee JDC; Hogendorf WJ; van der Marel GA; Huebner J

Author Email Address: christian.theilacker@uniklinik-freiburg.de

Corporate Source: Univ Med Ctr Freiburg, Ctr Chron Immunodeficiency, D-79106

Freiburg//Germany/ (REPRINT); Univ Med Ctr Freiburg, Ctr Chron

Immunodeficiency, D-79106 Freiburg//Germany/; Univ Freiburg, Freiburg//Germany/; Univ

Med Ctr Freiburg, Ctr Infect Dis & Travel Med, D-79106 Freiburg//Germany/; Leiden

Univ, Leiden Inst Chem NL-2300 RA Leiden//Netherlands/

Journal: JOURNAL OF INFECTIOUS DISEASES, 2012, V 205, N7 (APR 1), P 1076-1085

ISSN: 0022-1899 Publication Date: 20120401

Digital Object Identifier: 10.1093/infdis/jis022

Publisher: OXFORD UNIV PRESS INC, JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA

Funding: This study was supported by the German Federal Ministry of Education and

Research (grant number BMBF 01 EO 0803).

Funding Organization -- Grant Number:

German Federal Ministry of Education and Research -- BMBF 01 EO 0803

Language: English Document Type: ARTICLE (ABSTRACT AVAILABLE)

Title: Protection Against Staphylococcus aureus by Antibody to the

Polyglycerol phosphate Backbone of Heterologous Lipoteichoic Acid

Abstract: Type 1 lipoteichoic acid (LTA) is present in many clinically important gram-positive bacteria, including enterococci, streptococci... .the present study, we show that antibodies against E. faecalis LTA also bind to type 1 LTA from other gram-positive species and opsonized Staphylococcus epidermidis and Staphylococcus aureus strains as well as group B streptococci. Inhibition studies using teichoic acid oligomers indicated that cross-reactive opsonic antibodies bind to the teichoic acid backbone. Passive immunization with rabbit antibodies against E. faecalis LTA promoted the clearance of...

Descriptors:

Identifiers: ...MACROPHAGE SCAVENGER RECEPTOR; GRAM-POSITIVE BACTERIA; CAPSULAR

POLYSACCHARIDE; ENTEROCOCCUS-FAECALIS; MONOCLONAL -ANTIBODY;

STREPTOCOCCUS-PNEUMONIAE; CONJUGATE VACCINES; TEICHOIC -ACIDS; CELL-WALL; VIRULENCE

Research Fronts:

Dialog eLink:

5/3, K/4 (Item 2 from file: 34)

DIALOG(R) File 34: SciSearch(R) Cited Ref Sci

(c) 2012 The Thomson Corp. All rights reserved.

06141338 Genuine Article#: XX775 No. References: 31

Title: Immunopathologic features of Staphylococcus epidermidis-induced endophthalmitis in the rat

Author: Ravindranath RMH (REPRINT); Hasan SA; Mondino BJ

Corporate Source: UNIV SO CALIF, CTR ORAL OFACIAL MOL BIOL, 2250 ALCAZAR ST/LOS ANGELES/CA 90033 (REPRINT); UNIV CALIF LOS ANGELES, DORIS STEIN EYE RES CTR, JULES STEIN EYE INST/LOS ANGELES/CA 90024

Journal: CURRENT EYE RESEARCH, 1997, V 16, N10 (OCT), P 1036-1043

ISSN: 0271-3683 Publication Date: 19971000

Publisher: OXFORD UNIV PRESS, GREAT CLARENDON ST, OXFORD, ENGLAND OX2 6DP

Language: English Document Type: ARTICLE (ABSTRACT AVAILABLE)

Title: Immunopathologic features of Staphylococcus epidermidis-induced endophthalmitis in the rat

Abstract: Purpose. To investigate the clinical, histopathologic and immunologic responses to Staphylococcus epidermidis endophthalmitis in a rat model.

Methods. Experimental rats received an intravitreal injection of viable... infiltrate in vitreous, and levels of serum and vitreous IgM, IgG and IgA to glycerol teichoic acid (CTA), the major antigenic determinant of S. epidermidis cell wall, were all measured from day 1 to day 30 after injection.

Results. The ocular inflammation was largely resolved by day 14... of anti-GTA IgM was observed in vitreous of S. epidermidis-infected rats on day 1 and declined by day 7. In contrast to vitreous antibodies, serum anti-GTA IgM antibodies...

Descriptors: ...enzyme-linked immunosorbent assay (ELISA); endophthalmitis; IgM antibodies; Staphylococcus epidermidis; vitreous; rat

Research Fronts: 95-1513-001 (NATURAL ANTIBODIES; PROTEIN ANTIGENS; IMMUNOMODULATION OF EXPERIMENTAL AUTOIMMUNE MYASTHENIA GRAVIS; MONOCLONAL AUTOANTIBODY; SOMATIC MUTATIONS)

Cited References:

Dialog eLink:

5/3, K/5 (Item 3 from file: 34)

DIALOG(R) File 34: SciSearch(R) Cited Ref Sci

(c) 2012 The Thomson Corp. All rights reserved.

01236859 Genuine Article#: GGB54 No. References: 34

Title: ACTIVATION OF MONONUCLEAR IMMUNE CELLS IN RESPONSE TO STAPHYLOCOCCAL LIPOTEICHOIC ACID

Author: OHSHIMA Y; KOHL; BEUTH J; BURRICHTER H; OETTE K; PULVERER G

Corporate Source: UNIV COLOGNE, INST MED MICROBIOL & HYG, GOLDENFELSSTR 19-21/D-5000 COLOGNE 41//FED REP GER; ST MARIANNA MED UNIV, SCH MED, DEPT MICROBIOL/KAWASAKI/KANAGAWA 213/JAPAN; UNIV COLOGNE, INST CLIN CHEM/D-5000 COLOGNE 41//FED REP GER

Journal: ZENTRALBLATT FUR BAKTERIOLOGIE-INTERNATIONAL JOURNAL OF MEDICAL

MICROBIOLOGY, 1991, V 275, N3, P 374-381

Language: ENGLISH Document Type: ARTICLE (Abstract Available)

10601171

Abstract: ...A murine tumor necrosis-like factor (TNF-like) was induced in the sera of CD-1 mice which had been primed with heat/formalin-inactivated *Propionibacterium avidum* KP-40 and subsequently exposed to LTA extracted from *Staphylococcus saprophyticus* strain S1. Monoclonal antibody against murine TNF (anti-TNF) significantly inhibited the cytostatic activity of mice sera against...

Descriptors:

Identifiers: ...TUMOR NECROSIS FACTOR; INDUCED SERUM FACTOR; FACTOR CAECHECTIN; TEI CHOIC-ACIDS; RESISTANCE; EXPRESSION; ENDOTOXIN; SAPROPHYTICUS; ADHERENCE; INFECTION

Research Fronts:

Dialog eLink:

5/3, K/6 (Item 1 from file: 72)

DIALOG(R) File 72: EMBASE

(c) 2012 Elsevier B.V. All rights reserved.

0081012584 EMBASE/MEDLINE No: 2006072561

Prospects for active and passive immunization against *Staphylococcus aureus*

Shinefield H.R.; Black S.

University of California, San Francisco, CA, United States

Corresp. Author/Affil: Shinefield H.R.: University of California, San Francisco, CA, United States

Pediatric Infectious Disease Journal (Pediatr. Infect. Dis. J.) (United States)
February 1, 2006, 25/2 (167-168)

CODEN: PIDJDE ISSN: 0891-3668

Item Identifier (DOI): 10.1097/01.inf.0000199887.18267.9a

Document Type: Journal; Short Survey Record Type: Citation

Language: English

Number of References: 15

Prospects for active and passive immunization against *Staphylococcus aureus*

Drug Descriptors:

alpha toxin--drug development--dv; bacterial toxin--drug development--dv; monoclonal antibody--drug development--dv; monoclonal antibody--pharmacology--pd; polysaccharide vaccine--clinical trial--ct; polysaccharide vaccine--drug therapy--dt; polysaccharide vaccine--intramuscular drug administration--im; *Pseudomonas* exotoxin; *Staphylococcus* vaccine--clinical trial--ct; *Staphylococcus* vaccine--drug therapy--dt; *Staphylococcus* vaccine--intramuscular drug administration--im; teichoic acid--drug development--dv; teichoic acid--pharmacology--pd; toxic shock syndrome toxin 1--drug development--dv; unclassified drug; virulence factor--drug development--dv

Medical Descriptors:

* active immunization; * passive immunization; * *Staphylococcus aureus*; * *Staphylococcus* infection--drug therapy--dt; * *Staphylococcus* infection--prevention--pc

Drug Terms (Uncontrolled): altastaph; monoclonal antibody 12 9--drug development--dv; monoclonal antibody 12 9--pharmacology--pd; pantovalentine leukocidin--drug development--dv; staphvax

Medical Terms (Uncontrolled):

CAS Registry Number: 9041-38-7 (teichoic acid); 164909-28-8 (toxic shock syndrome toxin 1)

SECTION HEADINGS:

Dial og eLink:

5/3, K/7 (Item 2 from file: 72)

DIALCOG File 72: EMBASE

(c) 2012 Elsevier B.V. All rights reserved.

0080840790 EMBASE/MEDLINE No: 2005485429

Prevention of Staphylococcus aureus infections: Advances in vaccine development

Shinefield H.R.; Black S.

2240 Hyde Street, San Francisco, CA 94109, United States; Department of Pediatrics and Dermatology, University of California School of Medicine, 2240 Hyde Street, San Francisco, CA 94109, United States

Author email: Henryshinefield@aol.com steve.black@p.org

Corresp. Author/Affil: Shinefield H.R.: 2240 Hyde Street, San Francisco, CA 94109, United States

Corresp. Author Email: Henryshinefield@aol.com

Expert Review of Vaccines (Expert Rev. Vaccines) (United Kingdom) October 1, 2005, 4/5 (669-676)

CODEN: ERVXA ISSN: 1476-0584 eISSN: 1744-8395

Item Identifier (DOI): 10.1586/14760584.4.5.669

Document Type: Journal ; Review Record Type: Abstract

Language: English Summary language: English

Number of References: 47

Prevention of Staphylococcus aureus infections: Advances in vaccine development

Staphylococcus aureus is a ubiquitous bacterial species that causes serious disease in a minority of carriers...

Drug Descriptors:

* Staphylococcus vaccine--adverse drug reaction--ae; * Staphylococcus vaccine--clinical trial--ct; * Staphylococcus vaccine--drug combination--cb; * Staphylococcus vaccine--drug development--dv; * Staphylococcus vaccine--drug dose--do; * Staphylococcus vaccine--drug therapy--dt; * Staphylococcus vaccine--intramuscular drug administration--im; * Staphylococcus vaccine--pharmacology--pd; ... protein; hemolysin; hyaluronidase; inactivated vaccine--clinical trial--ct; inactivated vaccine--drug therapy--dt; leukocidin; metalloproteinase; monoclonal antibody--drug therapy--dt; monoclonal antibody--pharmacology--pd; phospholipase C; protein A; Pseudomonas exotoxin--clinical trial--ct; Pseudomonas exotoxin--drug therapy--dt; Pseudomonas exotoxin--intramuscular drug administration--im; Pseudomonas exotoxin--pharmacology--pd; teichoic acid--pharmacology--pd; unclassified drug; virulence factor--clinical trial--ct; virulence factor--drug therapy--dt...

Medical Descriptors:

* Staphylococcus infection--drug therapy--dt; * Staphylococcus infection--etiology--et; * Staphylococcus infection--prevention--pc; ... infection prevention; medical expert; morbidity; mortality; nonhuman; priority journal; review; side effect--side effect--si; Staphylococcus aureus; vaccination; virus strain

Drug Terms (Uncontrolled): altastaph--adverse drug reaction--ae; altastaph--clinical trial--ct; altastaph--drug therapy--dt; clumping factor monoclonal antibody--pharmacology--pd; lipoteichoic acid monoclonal antibody--drug therapy--dt; lipoteichoic acid monoclonal antibody--pharmacology--pd; mutant toxic shock syndrome toxin 1--clinical trial--ct; mutant toxic shock syndrome toxin 1--drug development--dv; mutant toxic shock syndrome toxin 1--drug therapy--dt; mutant toxic shock syndrome toxin 1--pharmacology--pd; recombinant pseudomonas aeruginosa exotoxin a--clinical trial--ct; recombinant pseudomonas aeruginosa exotoxin a...

Medical Terms (Uncontrolled):

10601171

CAS Registry Number: ...83-3 (leukocidin); 81669-70-7 (metalloproteinase); 9001-86-9 (phospholipase C); 9041-38-7 (teichoic acid)

SECTION HEADINGS:

Dialog eLink:

5/3, K/8 (Item 3 from file: 72)

DIALOG(R) File 72: EMBASE

(c) 2012 Elsevier B.V. All rights reserved.

0068532775 EMBASE/MEDLINE No: 12011760

Induction of cytokine production in human T cells and monocytes by highly purified lipoteichoic acid: involvement of Toll-like receptors and CD14.

Ellingsen E.; Morath S.; Flo T.; Schromm A.; Hartung T.; Thiernemann C.; Espevik T.; Golenbock D.; Foster D.; Solberg R.; Aasen A.; Wang J.

Institute for Surgical Research, Rikshospitalet - National Hospital, N-0027 Oslo, Norway.

Corresp. Author/Affil: Ellingsen E.; Institute for Surgical Research, Rikshospitalet - National Hospital, N-0027 Oslo, Norway.

Medical science monitor : international medical journal of experimental and clinical research (Med. Sci. Monit.) (Poland) May 1, 2002, 8/5 (BRI49-156)
ISSN: 1234-1010

Document Type: Journal ; Article Record Type: Abstract File Segment: Medline

Language: English

BACKGROUND: The pro-inflammatory potential of lipoteichoic acid (LTA) from *Staphylococcus aureus* is controversial. The present study was undertaken to examine the ability of highly purified... elicited a time and concentration dependent release of tumor necrosis factor alpha (TNF-alpha), interleukin-1 beta (IL-1 beta), IL-6 and IL-8. Messenger RNA encoding TNF-alpha, IL-1 beta and IL-6 seemed to be accumulated in monocytes and T cells, but not... chinese hamster ovary cells conferred responsiveness to LTA. However, antibodies directed towards TLR2 (clone TL2.1) or TLR4 (clone HTA125) failed to inhibit TNF-alpha release induced by LTA in both...

Drug Descriptors:

* CD14 antigen; * cell surface receptor; * cytokine; * Drosophila protein; * lipopolysaccharide--pharmacology--pd; * membrane protein; * teichoic acid--pharmacology--pd

actin; lipoteichoic acid; messenger RNA; monoclonal antibody; toll like receptor; toll like receptor 2; toll like receptor 4

Medical Descriptors:

CAS Registry Number: 56411-57-5 (lipoteichoic acid); 9041-38-7 (teichoic acid); 409141-78-2 (toll like receptor); 203811-81-8 (toll like receptor 2); 203811...

SECTION HEADINGS:

Dialog eLink:

5/3, K/9 (Item 1 from file: 155)

DIALOG(R) File 155: MEDLINE(R)

(c) format only 2012 Dialog. All rights reserved.

19696254 PMID: 19268719

Safety and pharmacokinetics of a chimerized anti-lipoteichoic acid monoclonal
Page 8

antibody in healthy adults.

Weisman Leonard E; Fischer Gerald W; Thackray Helen M; Johnson Karen E; Schuman Richard F; Mandy George T; Stratton Beth E; Adams Karen M; Kramer William G; Mond James J

Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA.
lweisman@bcm.edu

International Immunopharmacology (Netherlands) May 2009, 9 (5) p639-44, ISSN: 1878-1705--Electronic 1567-5769--Linking Journal Code: 100965259

Publishing Model: Print-Electronic

Document type: Journal Article; Research Support, Non-U.S. Gov't

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

Safety and pharmacokinetics of a chimerized anti-lipoteichoic acid monoclonal antibody in healthy adults.

A chimerized (murine/human) monoclonal antibody (pagibaximab) against lipoteichoic acid (LTA) and protective in animal models for coagulase-negative staphylococci (CONS) and Staphylococcus aureus bacteremia, was developed for prevention of staphylococcal infection in high-risk populations. This open... was approximately 33 days. Opsonophagocytic activity of serum samples on a human clinical isolate of Staphylococcus epidermidis in a standard bacterial killing assay was dose-related, and peaked at a mean of 88.5 and 95.5% at 1:90 dilution for 3 and 10 mg/kg groups, respectively. Serum anti-LTA and opsonophagocytic... and 10 mg/kg administered as a single intravenous dose in healthy adults appears to: 1) provide preliminary safety and tolerability data, 2) produce dose-related serum anti-LTA and opsonophagocytic... (

Descriptors: *Anti-Bacterial Agents--pharmacokinetics--PK; *Antibodies, Monoclonal--pharmacokinetics--PK; *Lipopolysaccharides--immunology--IM *Neutrophils--metabolism--ME; *Staphylococcal Infections--therapy--TH; *Staphylococcus aureus--immunology--IM *Staphylococcus epidermidis--immunology--IM *Teichoic Acids--immunology--IM; ... Animals; Anti-Bacterial Agents--administration and dosage--AD; Anti-Bacterial Agents--adverse effects--AE; Antibodies, Monoclonal--administration and dosage--AD; Antibodies, Monoclonal--adverse effects--AE; Dose-Response Relationship, Drug; Half-Life; Humans; Injections, Intravenous; Mice; Middle Aged...

Named Person:

Chemical Name: Anti-Bacterial Agents; Antibodies, Monoclonal; Lipopolysaccharides;

Recombinant Fusion Proteins; Teichoic Acids; pagibaximab; lipoteichoic acid

Dialog eLink:

5/3, K/10 (Item 2 from file: 155)

DIALOG(R) File 155: MEDLINE(R)

(c) format only 2012 Dialog. All rights reserved.

18220480 PMID: 17283098 Record Identifier: PMC1865665

Evidence of immunostimulating lipoprotein existing in the natural lipoteichoic acid fraction.

Hashimoto Masahito; Furuyashiki Mai; Kaseya Ryoko; Fukada Yuka; Akimaru Mai; Aoyama Kazuo; Okuno Toshiomi; Tamura Toshihide; Kiriaka Teruo; Kiriaka Fumiko; Eiraku Nobutaka; Mrioka Hirofumi; Fujimoto Yukari; Fukase Koichi; Takashi ge Katsumi; Mriya Yoichi; Kusumoto Shouichi; Suda Yasuo

Department of Nanostructure and Advanced Materials, Kagoshima University, Korimoto 1-21-40, Kagoshima 890-0065, Japan.

Infection and immunity (United States) Apr 2007, 75 (4) p1926-32, ISSN: 0019-9567--Print 0019-9567--Linking Journal Code: 0246127

10601171

Publishing Model Print-Electronic; Qtes J Exp Med. 1999 Jun 7;189(11):1777-82 PM D 10359581; Qtes Infect Immun. 1999 Jan;67(1):173-81 PM D 9864212; Qtes Biochem Biophys Res Commun. 2000 Jun 24;273(1):164-9 PM D 10873580; Qtes Nature. 2000 Dec 7;408(6813):740-5 PM D 11130078; Qtes J Exp Med. 2001 Feb 5;193(3):393-7 PM D 11157059; Qtes Infect Immun. 2001 Mar;69(3):1477-82 PM D 11179315; Qtes Nat Immunol. 2001 Apr;2(4):346-52 PM D 11276206; Qtes Nature. 2001 Apr 26;410(6832):1099-103 PM D 11323673; Qtes Int Immunol. 2001 Jul;13(7):933-40 PM D 11431423; Qtes Nature. 2001 Oct 18;413(6857):732-8 PM D 11607032; Qtes Curr Opin Immunol. 2002 Feb;14(1):103-10 PM D 11790539; Qtes J Immunol. 2002 Apr 15;168(8):4012-7 PM D 11937558; Qtes J Exp Med. 2002 Jun 17;195(12):1635-40 PM D 12070290; Qtes J Immunol. 2002 Jul 1;169(1):10-4 PM D 12077222; Qtes J Biol Chem. 2003 Aug 29;278(35):32552-60 PM D 12807870; Qtes Infect Immun. 2003 Oct;71(10):5541-8 PM D 14500472; Qtes Science. 2004 Mar 5;303(5663):1526-9 PM D 14976262; Qtes Eur J Biochem. 1992 Aug 1;207(3):1063-75 PM D 1499552; Qtes Int Immunol. 2004 Oct;16(10):1431-7 PM D 15326096; Qtes Infect Immun. 2005 Apr;73(4):2411-23 PM D 15784587; Qtes Int Immunol. 2006 Feb;18(2):355-62 PM D 16373361; Qtes J Immunol. 2006 Sep 1;177(5):3162-9 PM D 16920954; Qtes FEMS Microbiol Immunol. 1991 Aug;3(4):211-8 PM D 1718341; Qtes Infect Immun. 1991 Dec;59(12):4614-20 PM D 1937822; Qtes Br J Cancer. 1988 Jan;57(1):70-3 PM D 3279996; Qtes Br J Cancer. 1987 Dec;56(6):797-9 PM D 3435705; Qtes Br J Cancer. 1985 May;51(5):739-42 PM D 3888244; Qtes Infect Immun. 1995 Jan;63(1):57-65 PM D 7806384; Qtes FEMS Immunol Med Microbiol. 1995 Oct;12(2):97-112 PM D 8589669; Qtes J Biochem. 1997 Apr;121(4):779-86 PM D 9163531; Qtes FEMS Immunol Med Microbiol. 1997 Dec;19(4):275-83 PM D 9537752; Qtes Science. 1998 Dec 11;282(5396):2085-8 PM D 9851930; Qtes J Biol Chem. 1999 Jun 18;274(25):17406-9 PM D 10364168

Document type: Journal Article; Research Support, Non-U.S. Gov't

Languages: ENGLISH

Main Citation Owner: NLM

Other Citation Owner: NLM

Record type: MEDLINE; Completed

... Eh-AF in an LTA fraction possesses activity. In this study, we established a mouse monoclonal antibody neutralizing the activity of Eh-AF and investigated its inhibitory effects. Monoclonal antibody (MAbEh1) was established by the immunization of BALB/c mice with Eh-AF, followed... the production of IL-6 by LTA fraction from not only E. hirae but also Staphylococcus aureus, while it failed to block that of lipopolysaccharide, suggesting that the antibody recognized a... found to inhibit the activity of immunostimulating synthetic lipopeptides, Pam3CSK4 and FSL-1. These results suggest that MAbEh1 neutralizes the activity of lipoprotein-like compounds which is responsible...

Descriptors: *Antibodies, Bacterial--immunology--IM *Antibodies, Monoclonal--immunology--IM *Enterococcus--immunology--IM *Lipopolysaccharides--immunology--IM *Lipopeptides--immunology--IM *Teichoic Acids--immunology--IM; *ILP; Lipoproteins--isolation and purification--IP; Mice; Mice, Inbred BALB C; Models, Animal; Neutralization Tests; Staphylococcus aureus--immunology--IM Teichoic Acids--isolation and purification--IP

Named Person:

Chemical Name: Antibodies, Bacterial; Antibodies, Monoclonal; Interleukin-6;

Lipopolysaccharides; Lipopeptides; Teichoic Acids; Lipoteichoic acid

Dialog eLink:

5/3, K/11 (Item 3 from file: 155)

DIALOG File 155: MEDLINE(R)

(c) format only 2012 Dialog. All rights reserved.

14736802 PM D: 11447182 Record Identifier: PMC85956

Differential roles of interleukin-18 (IL-18) and IL12 for induction of gamma interferon by staphylococcal cell wall components and superantigens.

10601171

Stuyt R J; Netea M G; Kim S H; Novick D; Rubinstein M; Kullberg B J; Van der Meer J W; Di Nareello C A
Department of Medicine, University of Colorado Health Sciences Center, Denver, Colorado, USA

Infection and immunity (United States) Aug 2001 , 69 (8) p5025-30 , ISSN: 0019-9567 - Print 0019-9567 - Linking Journal Code: 0246127

Contract/Grant No.: AI-15614; AI; NIAID NIH HHS United States
Publishing Model Print; Qtes Immunity. 1999 Jan;10(1):127-36 PM D 10023777 ; Qtes J Infect Dis. 1999 Mar;179(3):646-52 PM D 9952371; Qtes Immunity. 1999 Oct;11(4):443-51 PM D 10549626; Qtes Proc Natl Acad Sci U S A. 2000 Feb 1;97(3):1190-5 PM D 1065506; Qtes Proc Natl Acad Sci U S A. 2000 Dec 5;97(25):13766-71 PM D 11095740; Qtes Nature. 2000 Dec 7;408(6813):740-5 PM D 11130078; Qtes J Exp Med. 2001 Feb 5;193(3):393-7 PM D 11157059; Qtes J Immunol. 1992 Jun 1;148(11):3433-40 PM D 1350290; Qtes Infect Immun. 1991 May;59(5):1709-15 PM D 1902195; Qtes J Clin Invest. 1991 Jun;87(6):1925-35 PM D 2040686; Qtes Science. 1990 May 11;248(4956):705-11 PM D 2185544; Qtes Proc Natl Acad Sci U S A. 1989 Nov;86(22):8941-5 PM D 2479030; Qtes Infect Immun. 1989 Feb;57(2):590-5 PM D 2492265; Qtes J Clin Invest. 1988 Apr;81(4):1162-72 PM D 3258319; Qtes N Engl J Med. 1980 Dec 18;303(25):1429-35 PM D 7432401; Qtes Nature. 1995 Nov 2;378(6552):88-91 PM D 7477296; Qtes J Immunol. 1995 Jun 1;154(11):5832-41 PM D 7538532; Qtes J Exp Med. 1993 Sep 1;178(3):1041-8 PM D 8102388; Qtes FEMS Immunol Med Microbiol. 1993 Oct;7(3):281-7 PM D 8275059; Qtes Infect Immun. 1993 Aug;61(8):3342-50 PM D 8335365; Qtes Blood. 1996 Mar 15;87(6):2095-147 PM D 8630372; Qtes Immunity. 1996 May;4(5):471-81 PM D 8630732; Qtes Infect Immun. 1996 Jun;64(6):1906-12 PM D 8675286; Qtes Science. 1997 Jan 10;275(5297):206-9 PM D 8999548; Qtes Nature. 1997 Apr 10;386(6625):619-23 PM D 9121587; Qtes J Clin Invest. 1998 Feb 1;101(3):711-21 PM D 9449707; Qtes Immunity. 1998 Mar;8(3):383-90 PM D 9529155; Qtes J Immunol. 1998 Oct 1;161(7):3400-7 PM D 9759857; Qtes J Infect Dis. 1998 Dec;178(6):1830-4 PM D 9815245; Qtes J Allergy Clin Immunol. 1999 Jan;103(1 Pt 1):11-24 PM D 9893178; Qtes J Biol Chem 1999 Jun 18;274(25):17406-9 PM D 10364168

Document type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.

Languages: ENGLISH

Main Citation Owner: NLM

Other Citation Owner: NLM

Record type: MEDLINE; Completed

...TNF) were used to neutralize IL-18 and TNF, respectively, whereas an anti-IL-12 monoclonal antibody was used to neutralize IL-12 and the IL-1 receptor antagonist (IL-1Ra) was used to block IL-1 receptors. Heat-killed Staphylococcus epidermidis and Staphylococcus aureus, as well as the staphylococcal superantigens toxic shock syndrome toxin-1 (TSST-1) and staphylococcal enterotoxin B (SEB) induced gamma interferon (IFN-gamma) production. Staphylococcus spp.-induced production of IFN-gamma required the presence of endogenous IL-18, IL-12, and TNF. In contrast, TSST-1-induced IFN-gamma was not significantly reduced in the presence of IL-18BP, anti-IL-1... was significantly inhibited only by anti-IL-12 antibodies, indicating that endogenous IL-18, IL-1, and TNF are not required for SEB-induced IFN-gamma. In conclusion, the mechanisms of...

Descriptors: *Bacterial Toxins; *Interferon-gamma--biosynthesis--BI; *Interleukin-12--immunology--IM; *Interleukin-18--immunology--IM; *Staphylococcus aureus--immunology--IM; *Staphylococcus epidermidis--immunology--IM; ...immunology--IM; Enterotoxins--immunology--IM; Humans; Lipopolysaccharides--immunology--IM; Peptidoglycan--immunology--IM; Superantigens--immunology--IM; Teichoic Acids--immunology--IM; Tumor Necrosis Factor-alpha--biosynthesis--BI

Named Person:

Chemical Name: Antigens, Bacterial; Bacterial Toxins; Enterotoxins; Interleukin-18; Lipopolysaccharides; Peptidoglycan; Superantigens; Teichoic Acids; Tumor Necrosis Factor-alpha; enterotoxin B; Staphylococcal; Interleukin-12; enterotoxin B, staphylococcal; lipoteichoic acid...

Dialog eLink:

5/3, K/12 (Item 4 from file: 155)

Dialog File 155: MEDLINE(R)

(c) format only 2012 Dialog. All rights reserved.

14581609 PM D: 11254557 Record Identifier: PMD98129

Synergistic effect of muramyl dipeptide with lipopolysaccharide or lipoteichoic acid to induce inflammatory cytokines in human monocytic cells in culture.

Yang S; Tarrai R; Akashi S; Takeuchi O; Akira S; Sugawara S; Takada H

Department of Microbiology and Immunology, Tohoku University School of Dentistry, Aoba-ku, Sendai 980-8575, Japan.

Infection and Immunity (United States) Apr 2001; 69(4):p2045-53, ISSN: 0019-9567--Print 0019-9567--Linking Journal Code: 0246127

Publishing Model Print; Cites Curr Opin Immunol. 1999 Feb;11(1):13-8 PM D 10047546; Cites Infect Immun. 1999 Apr;67(4):1623-32 PM D 10084995; Cites J Immunol. 1999 Apr 1;162(7):3749-52 PM D 10201887; Cites J Immunol. 1999 May 15;162(10):5666-70 PM D 10229796; Cites Int J Immunopharmacol. 1999 Mar;21(3):227-32 PM D 10348372; Cites J Exp Med. 1999 Jun 7;189(11):1777-82 PM D 10359581; Cites J Biol Chem. 1999 Jun 18;274(25):17406-9 PM D 10364168; Cites J Immunol. 1999 Jul 1;163(1):1-5 PM D 10384090; Cites Int Immunol. 2000 Jan;12(1):113-7 PM D 10607756; Cites J Immunol. 2000 Jan 15;164(2):554-7 PM D 10623793; Cites J Immunol. 2000 Jan 15;164(2):966-72 PM D 10623846; Cites Infect Immun. 2000 Mar;68(3):1235-42 PM D 10678932; Cites J Immunol. 2000 Apr 1;164(7):3471-5 PM D 10725698; Cites Cytokine Growth Factor Rev. 2000 Sep;11(3):219-32 PM D 10817965; Cites Nat Genet. 2000 Jun;25(2):187-91 PM D 10835634; Cites J Immunol. 2000 Jul 15;165(2):618-22 PM D 10878331; Cites Nature. 2000 Aug 17;406(6797):782-7 PM D 10963608; Cites Cancer Res. 1979 Nov;39(11):4756-9 PM D 115579; Cites Immunol Today. 1992 Jul;13(7):271-6 PM D 1388655; Cites Microbiol Immunol. 1992;36(11):1155-71 PM D 1491619; Cites Sci Am. 1992 Aug;267(2):54-61 PM D 1641625; Cites J Leukoc Biol. 1990 Feb;47(2):164-9 PM D 2303750; Cites Microbiol Immunol. 1990;34(3):323-35 PM D 2352499; Cites Biochem Biophys Res Commun. 1985 Sep 30;131(3):1160-7 PM D 2996538; Cites Infect Immun. 1987 May;55(5):1279-88 PM D 3106217; Cites Cancer Res. 1987 Nov 1;47(21):5616-9 PM D 3664468; Cites Infect Immun. 1987 Feb;55(2):409-13 PM D 3804443; Cites Cancer Lett. 1984 Jun;23(2):159-65 PM D 6378362; Cites Infect Immun. 1982 Feb;35(2):417-24 PM D 7035362; Cites J Exp Med. 1995 Dec 1;182(6):1673-82 PM D 7500012; Cites J Biol Chem. 1995 Apr 28;270(17):9904-10 PM D 7537270; Cites Annu Rev Immunol. 1995;13:437-57 PM D 7542010; Cites Infect Immun. 1995 Jan;63(1):57-65 PM D 7806384; Cites Infect Immun. 1993 Dec;61(12):5252-60 PM D 8225600; Cites Proc Natl Acad Sci U S A. 1993 Mar 15;90(6):2365-9 PM D 8460147; Cites Infect Immun. 1996 Feb;64(2):657-9 PM D 8550222; Cites FEMS Immunol Med Microbiol. 1995 Oct;12(2):97-112 PM D 8589669; Cites Infect Immun. 1996 Apr;64(4):1426-31 PM D 8606111; Cites FEMS Immunol Med Microbiol. 1997 Jan;17(1):49-55 PM D 9012443; Cites Infect Immun. 1997 Mar;65(3):858-64 PM D 9038288; Cites Nephron. 1997;75(4):438-43 PM D 9127331; Cites J Exp Med. 1998 Jul 20;188(2):305-15 PM D 9670043; Cites Immunity. 1998 Jul;9(1):143-50 PM D 9697844; Cites Nature. 1998 Sep 17;395(6699):284-8 PM D 9751057; Cites J Exp Med. 1998 Dec 7;188(11):2091-7 PM D 9841923; Cites Science. 1998 Dec 11;282(5396):2085-8 PM D 9851930; Cites J Exp Med. 1999 Feb 15;189(4):605-9 PM D 9989974; Cites J Exp Med. 1999 Feb 15;189(4):615-25 PM D 9989976

Document type: Journal Article; Research Support, Non-U.S. Gov't

Languages: ENGLISH

Main Citation Owner: NLM

Other Citation Owner: NLM

Record type: MEDLINE; Completed

An analog of 1 α ,25-di hydroxyvitamin D₃, 22-oxyacal citriol (CCT), differentiated human monocytic THP-1 and U937 cells to express membrane CD14 and rendered the cells responsive to bacterial cell surface components. Both THP-1 and U937 cells expressed Toll-like receptor 4 (TLR4) on the cell surface and TLR4... treatment. In contrast, CCT-treated U937 cells scarcely expressed TLR2 mRNA, while CCT-treated THP-1 cells expressed this transcript. Muramyl dipeptide (MDP), itself exhibited only a weak ability to induce secretion of inflammatory cytokines such as

10601171

interleukin-8 (IL-8) in the OCT-differentiated THP-1 cells but showed marked synergistic effects with Salmonella lipopolysaccharide (LPS) or lipoteichoic acid (LTA) from Staphylococcus aureus, both of which exhibited strong activities. Combinatory stimulation with LPS plus LTA did not show a synergistic effect on OCT-differentiated THP-1 cells. Similar results were observed in OCT-differentiated U937 cells, although combination experiments were carried out only with MDP plus LPS. Anti-CD14 monoclonal antibody (MAb) M4, anti-TLR4 MAb HTA125, and the synthetic lipid A precursor LA-14... the IL-8-inducing activities of LTA as well as LPS on OCT-treated THP-1 cells, but these treatments increased MDP activity. OCT-treated THP-1 cells primed with MDP exhibited enhanced production of IL-8 upon stimulation with LPS, while... to TLRs, MyD88, to an extent similar to that for LPS in OCT-treated THP-1 cells. These findings suggested that LTA as well as LPS activated human monocyte cells in... (

Descriptors: ... PD; *Cytokines--biosynthesis--BI; *Drosophila Proteins; *Lipopolysaccharides--pharmacology--PD; *Monocytes--drug effects--DE; *Receptors, Immunologic; *Teichoic Acids--pharmacology--PD

Chemical Name: ... Factor 88; RNA, Messenger; Receptors, Cell Surface; Receptors, Immunologic; TLR2 protein, human; TLR4 protein, human; Teichoic Acids; Toll-Like Receptor 2; Toll-Like Receptor 4; Toll-Like Receptors;

Acetylmuramyl-Alanyl-isoglutamine...

Dialog eLink:
5/3, K/13 (Item 5 from file: 155)
DIALOG(R) File 155: MEDLINE(R)
(c) format only 2012 Dialog. All rights reserved.

11990450 PMID: 7639108
Surface-associated proteins from Staphylococcus aureus demonstrate potent bone resorbing activity.

Nair S; Song Y; Meghji S; Reddi K; Harris M; Ross A; Poole S; Wilson M; Henderson B
Maxillofacial Surgery Research Unit, Eastman Dental Institute for Oral Health Care Sciences, London, United Kingdom
Journal of bone and mineral research - the official journal of the American Society for Bone and Mineral Research (UNITED STATES) May 1995, 10 (5) p226-34, ISSN: 0884-0431--Print 0884-0431--Linking Journal Code: 8610640
Publishing Model: Print
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed
Surface-associated proteins from Staphylococcus aureus demonstrate potent bone resorbing activity.

Staphylococcus aureus infections are associated with rapid bone destruction in conditions such as osteomyelitis, bacterial arthritis... is potentially inhibited by indometacin and can be completely blocked by high concentrations of interleukin-1 receptor antagonist or TNF- α . A neutralizing monoclonal antibody to murine TNF. The SAP fraction can stimulate fibroblasts or monocytes to release osteolytic... (

Descriptors: *Bacterial Proteins--toxicity--TO; *Bone Resorption--chemically induced--CI; *Membrane Proteins--toxicity--TO; *Staphylococcus aureus--metabolism--ME; Animals; Antibodies, Monoclonal--therapeutic use--TU; Bacterial Proteins--chemistry--CH; Bacterial Proteins--isolation and purification--IP; Bone Resorption... CH; Membrane Proteins--isolation and purification--IP; Mice; Microscopy, Electron; Molecular Weight; Radioimmunoassay; Receptors, Interleukin-1--antagonists and inhibitors--AI; Staphylococcal Infections--physiopathology--PP; Staphylococcus aureus--cytology--CY; Staphylococcus aureus--ultrastructure--UL; Streptomyces--metabolism--ME; Teichoic Acids--toxicity--TO; Tumor Cells, Cultured;

10601171

Tumor Necrosis Factor- α -immunology-IM

Named Person:

Chemical Name: Antibodies, Monoclonal ; Bacterial Proteins; Cytokines;

Lipopolysaccharides; Membrane Proteins; Receptors, Interleukin-1 ; Teichoic Acids;

Tumor Necrosis Factor- α ; Dipeptidase; Indomethacin; Lipoteichoic acid

Dialog eLink:

5/3, K/14 (Item 6 from file: 155)

DIALOG(R) File 155: MEDLINE(R)

(c) format only 2012 Dialog. All rights reserved.

11374534 PMID: 7909266

Influence of staphylococcal lipoteichoic acid on the frustrated phagocytosis of neutrophils against opsonized corneocytes.

Kato T; Terui T; Zhen Y X; Tagami H

Department of Dermatology, Tohoku University School of Medicine, Sendai, Japan.

Experimental dermatology (DENMARK) Aug 1993, 2 (4) p171-4, ISSN:

0906-6705--Print 0906-6705--Linking Journal Code: 9301549

Publishing Model: Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

Stratum corneum (SC) exerts a proinflammatory effect in the presence of complement.

When *Staphylococcus aureus* (S. aureus) invades the skin through damaged SC, neutrophils accumulate at the subcorneal portion... the binding between SC and neutrophils is mediated by interaction between C3bi and CR3 (Mac-1). Such enhanced interaction seems to function in the primary host defence mechanism against the invading... {

Descriptor: Complement C3b--physiology--PH; *Epidermis--cytology--CY;

*Lipopolysaccharides--pharmacology--PD; *Macrophage-1 Antigen--physiology--PH;

*Neutrophils--drug effects--DE; *Opsonin Proteins--immunology--IM

*Phagocytosis--drug effects--DE; *Receptors, Complement--physiology--PH; *

Staphylococcus aureus--chemistry--CH; *Teichoic Acids--pharmacology--PD;

Antibodies, Monoclonal--immunology--IM; Antibodies, Monoclonal--pharmacology--PD;

Antigens, CD--immunology--IM; Antigens, CD11; Cell Wall--chemistry--CH; Complement

Pathway, Alternative...--PH; Receptors, Complement--immunology--IM; Respiratory

Burst--drug effects--DE; *Staphylococcal* Skin Infections--physiopathology--PP;

Teichoic Acids--isolation and purification--IP

Named Person:

Chemical Name: Antibodies, Monoclonal ; Antigens, CD; Antigens, CD11;

Lipopolysaccharides ; Macrophage-1 Antigen; Opsonin Proteins; Receptors,

Complement ; Teichoic Acids; Lipoteichoic acid; Complement C3b

Dialog eLink:

5/3, K/15 (Item 7 from file: 155)

DIALOG(R) File 155: MEDLINE(R)

(c) format only 2012 Dialog. All rights reserved.

07986017 PMID: 6083437

Characterization of a monoclonal antibody specific for lipoteichoic acid from various gram-positive bacteria.

Hamada S; Furuta T; Okahashi N; Nishizawa T; Yamamoto T; Chiba J
 Microbiology and Immunology (JAPAN) 1984 , 28 (9) p1009-21 , ISSN:
 0385-5600 - Print 0385-5600 - Linking Journal Code: 7703966
 Publishing Model Print
 Document type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
 Languages: ENGLISH
 Main Citation Owner: NLM
 Record type: MEDLINE; Completed
 Characterization of a monoclonal antibody specific for lipoteichoic acid from
 various gram positive bacteria.

A hybrid cell line, 3G6, producing monoclonal antibody (mAb) against the
 polyglycerophosphate (PGP) backbone of lipoteichoic acids has been derived by the...
 ...S. sanguis, Micrococcus sp., and Actinomyces viscosus. Whole cells of serotype b
 S. mutans and Staphylococcus epidermidis were agglutinated upon addition of 3G6 mAb,
 while those of most other species were... (

Descriptors: *Antibodies, Monoclonal --immunology--IM *Gram-Positive Bacteria
 --immunology--IM *Lipopolysaccharides; *Phosphatidic Acids--immunology--IM; *
 Teichoic Acids--immunology--IM; Animals; Antibodies, Monoclonal --isolation and
 purification--IP; Antibody Specificity; Antigens, Bacterial--immunology--IM
 Epitopes--immunology--IM; Glucosyltransferases--immunology--IM

Named Person:

Enzyme No.: EC 2.4. 1. - (Glucosyltransferases)

Chemical Name: Antibodies, Monoclonal ; Antigens, Bacterial; Epitopes;

Lipopolysaccharides; Phosphatidic Acids; Teichoic Acids; lipoteichoic acid;

Glucosyltransferases

Dialog eLink:

5/3, K/16 (Item 1 from file: 156)

DIALOG File 156: ToxFile

(c) format only 2012 Dialog. All rights reserved.

1052843 NLM Doc No: CRI SP/98/ AI 28414-08 Sec. Source ID: CRI SP/98/ AI 28414-08
 REGULATION OF HUMAN IGE SYNTHESIS BY CYTOKINES

BUCKLEY RH

DUKE UNIVERSITY MEDICAL CENTER, BOX 2898, DURHAM, NC 27710

Source: Cisp Data Base National Institutes Of Health

City or State: NORTH CAROLINA Zip Code: 27710

Pub. Year: 1997

Sponsoring Agency: U.S. DEPT. OF HEALTH AND HUMAN SERVICES; PUBLIC HEALTH SERVICE;
 NATIONAL INST. OF HEALTH, NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

Award Type: Grant

Document type: Research

Languages: ENGLISH

Record type: Completed

...focus on T cells and the cytokines they produce and has the following specific
 aims: 1) to define the cytokine profiles and CD23 expression of T cell clones
 derived from high... (atopic states) for common or different T cell
 characteristics; 4) To determine the effects of Staphylococcus aureus cell wall
 products (teichoic acid, peptidoglycan) and enterotoxin B on rhlL-4-induced B cell
 IgE synthesis and CD23... (

Enzyme No.: Identifiers: Staphylococcus aureus; biological signal transduction; B
 lymphocyte; T lymphocyte; cell cell interaction; cell wall; polymerase chain...
 ...hypersensitivity; leukocyte activation /transformation; cytokine; interleukin 6;
 interferon; interleukin 4; interleukin 5; immunoregulation; immunoglobulin gene;
 monoclonal antibody; antibody formation; CD antigen; staphylococcal enterotoxin;

10601171
protein biosynthesis; integrin; T cell receptor ; tissue / cell ...
Gene Symbol :

Dialog eLink:
5/3, K/17 (Item 1 from file: 399)
DIALOG R File 399: CA SEARCH(R)
(c) 2012 American Chemical Society. All rights reserved.

155560473 CA: 155(21)560473c PATENT
Novel receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
Inventor (Author): Colonna, Marco; Bouchon, Axel
Location: USA
Patent: U.S. Pat. Appl. Publ. ; US 20030165875 A1 Date: 20030904
Application: US 2002103423 (20020320) *US 2001PV277238 (20010320)
Pages: 96pp.
CODEN: USXXCO
Language: English
Patent Classifications:
Class: 070613000; C12Q-001/68A; C07H-021/04B; C12P-021/02B; C12N-005/06B;
C07K-014/705B

Dialog eLink:
5/3, K/18 (Item 2 from file: 399)
DIALOG R File 399: CA SEARCH(R)
(c) 2012 American Chemical Society. All rights reserved.

151099228 CA: 151(5)99228b JOURNAL
Phase 1/2 double-blind, placebo-controlled, dose escalation, safety, and pharmacokinetic study of pagibaximab (BSYX-A110), an anti-staphylococcal monoclonal antibody for the prevention of staphylococcal bloodstream infections, in very-low-birth-weight neonates
Author: Weissman, Leonard E.; Thackray, Helen M.; Garcia-Prats, Joseph A.; Nesin, Mirjana; Schneider, Joseph H.; Fretz, Jennifer; Kokai-Kun, John F.; Mbind, James J.; Kramer, William G.; Fischer, Gerald W.
Location: Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA
Journal: Antimicrob. Agents Chemother.
Date: 2009
Volume: 53 Number: 7 Pages: 2879-2886
CODEN: AMACQJ
ISSN: 0066-4804
Language: English
Publisher: American Society for Microbiology

5/3, K/19 (Item 1 from file: 135)
DIALOG R File 135: NewsRx Weekly Reports
Page 16

(c) 2012 NewsRx. All rights reserved.

0000525980 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Recent research focus of reports from Harvard University, U.S.
Life Science Weekly, May 22, 2007, p.5013DOCUMENT TYPE: Expanded Reporting
LANGUAGE: English
RECORD TYPE: FULLTEXT
WORD COUNT: 1029

TEXT:

...U.S., is an immediate alert from NewsRx to identify developing directions of research. Study 1: Fresh data on pathology are presented in the report "Utilization of arterial blood gas measurements... sterilization was not associated with breast cancer risk (RR=0.95, 95% CI=0.88- 1.03). However, tubal sterilizations performed from 1970 to 1974 were inversely associated with risk (RR... while younger women had a suggested decreased risk (RR=0.87, 95% CI=0.72- 1.06)." The researchers concluded, "Overall, tubal sterilization was not associated with breast cancer risk." However... Longwood Avenue, Boston, MA 02115, USA. heather.eliasen@hanning.harvard.edu. Study 3: Immunization with Staphylococcus aureus clumping factor B, a major determinant in nasal carriage, reduces nasal colonization in a murine model. According to recent research published in the journal Infection and Immunity, "Staphylococcus aureus is responsible for a wide range of infections, including soft tissue infections and potentially... for staphylococcal infection. Previous studies with rodent models of nasal colonization have implicated capsule and teichoic acid as staphylococcal surface factors that promote colonization." "In this study, a mouse model of... lower levels of colonization than control animals exhibited," reported Schaffer and his colleagues. "A CfB monoclonal antibody (mAb) inhibited S. aureus binding to mouse cytokeratin 10. Passive immunization of mice with... scientists concluded. Schaffer and his coauthors published their study in Infection and Immunity (Immunization with Staphylococcus aureus clumping factor B, a major determinant in nasal carriage, reduces nasal colonization in a... Keywords: Boston, Massachusetts, United States, Staphylococcal Vaccine, Vaccine Development, Vaccine Efficacy, Mucosal Immunization, Immunology, Immunotherapy, Staphylococcus Aureus, Proteomics. This article was prepared by Life Science Weekly editors from staff and other...

5/3, K/20 (Item 2 from file: 135)
DIALCG(R) File 135: NewsRx Weekly Reports
(c) 2012 NewsRx. All rights reserved.

0000491643 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Researchers' findings from Harvard University, U.S., advance research
Pharma Business Week, April 9, 2007, p.2433DOCUMENT TYPE: Expanded Reporting
LANGUAGE: English
RECORD TYPE: FULLTEXT
WORD COUNT: 1209

TEXT:

U.S. is an immediate alert from NewsRx to identify developing directions of research. Study 1: Researchers detail in "Identification of long-range regulatory elements in the protocadherin-alpha gene cluster... encoded by three closely linked gene clusters (Pcdh-alpha, -beta, and gamma) that span nearly 1 million base pairs of DNA. The Pcdh-alpha gene cluster encodes a family of 14... this unusual form of monoallelic expression leads to the expression of two different Pcdh-alpha 1-12 V exons, one from each chromosome. The two remaining V exons in the cluster... Identification of two long-range cis-regulatory elements in the Pcdh-alpha gene cluster, HS5-1 and HS7. We show that HS5-1 is required for maximal levels of expression from the Pcdh-alpha1-12 and alphaC1 promoters... and colleagues, Harvard University. The researchers concluded: "The nearly cluster-wide requirement of the HS5-1 element is consistent with the possibility that the monoallelic expression of Pcdh-alpha V exons... h Staphylococcus aureus clumping factor B, a major determinant in nasal carriage, reduces nasal colonization in a murine model. According to recent research published in the journal Infection and Immunity, "Staphylococcus aureus is responsible for a wide range of infections, including soft tissue infections and potentially... for staphylococcal infection. Previous studies with rodent models of nasal colonization have implicated capsule and teichoic acid as staphylococcal surface factors that promote colonization." "In this study, a mouse model of... lower levels of colonization than control animals exhibited," reported Schaffer and his colleagues. "A CfB monoclonal antibody (mAb) inhibited S. aureus binding to mouse cyokeratin 10. Passive immunization of mice with... scientists concluded. Schaffer and his coauthors published their study in Infection and Immunity (Immunization with Staphylococcus aureus clumping factor B, a major determinant in nasal carriage, reduces nasal colonization in a... phosphate (beta-TCP). "The scaffolds provided support for the formation of bone tissue in collagen 1, fibrin, alginate, and pluronic F127 hydrogels during culturing in oscillating and rotating dynamic conditions." C... reported. "Histological evaluation including toluidine blue, alkaline phosphatase, and von Kossa staining was done at 1, 2, 4, and 6 weeks. Radiographic evaluation and high-resolution volumetric CT (VCT) scanning, expression...

5/3, K/21 (Item 3 from file: 135)
 DI ALOC(R) File 135: NewsRx Weekly Reports
 (c) 2012 NewsRx. All rights reserved.

0000472850 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Recent research from Harvard University, U.S., summarized
 Science Letter, March 20, 2007, p.4280

DOCUMENT TYPE: Expanded Reporting

LANGUAGE: English

RECORD TYPE: FULLTEXT

WORD COUNT: 1128

Study 1: Current study results from the report, "Comparison of nonuniform rotational distortion between mechanical IVUS and... significantly smaller in OCT compared with M-IVUS in the mild curve model (3.2 +/- 1.0 degrees vs. 6.9 +/- 2.1 degrees, p<0.01). Compared with the latter model, the average in angle differences was exaggerated in the acute curve model with M-IVUS (9.1 +/- 0.9 degrees vs. 6.9 +/- 2.1 degrees, p<0.05) but not with OCT (3.5 +/- 0.8 degrees vs. 3.2 +/- 1.0 degrees, p=not significant)," wrote Y. Kawase and colleagues, Harvard University.

The researchers concluded... mechanical IVUS and OCT using a phantom model. Ultrasound In Medicine and Biology, 2007;33(1):67-73).

10601171

For additional information, contact Y. Kawase, Massachusetts General Hospital, Cardiology Laboratory of Integrative... sterilization was not associated with breast cancer risk (RR=0.95, 95% CI=0.88-1.03). However, tubal sterilizations performed from 1970 to 1974 were inversely associated with risk (RR... while younger women had a suggested decreased risk (RR=0.87, 95% CI=0.72-1.06).

The researchers concluded, "Overall, tubal sterilization was not associated with breast cancer risk." However... Longwood Avenue, Boston, MA 02115, USA. heather_ellassen@hannig.harvard.edu.

Study 3: Immunization with Staphylococcus aureus clumping factor B, a major determinant in nasal carriage, reduces nasal colonization in a murine model.

According to recent research published in the journal Infection and Immunity, "Staphylococcus aureus is responsible for a wide range of infections, including soft tissue infections and potentially... for staphylococcal infection. Previous studies with rodent models of nasal colonization have implicated capsule and teichoic acid as staphylococcal surface factors that promote colonization."

"In this study, a mouse model of... lower levels of colonization than control animals exhibited," reported Schaffer and his colleagues. "A QfB monoclonal antibody (mAb) inhibited S. aureus binding to mouse cytokeratin 10. Passive immunization of mice with... scientists concluded.

Schaffer and his coauthors published their study in Infection and Immunity (Immunization with Staphylococcus aureus clumping factor B, a major determinant in nasal carriage, reduces nasal colonization in a... Keywords: Boston, Massachusetts, United States, Staphylococcal Vaccine, Vaccine Development, Vaccine Efficacy, Mucosal Immunization, Immunology, Immunotherapy, Staphylococcus Aureus, Proteomics.

This article was prepared by Science Letter editors from staff and other reports...

5/3, K/22 (Item 4 from file: 135)
DIALOG File 135: NewsRx Weekly Reports
(c) 2012 NewsRx. All rights reserved.

0000320684 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Researchers from the United States report details of new studies and findings in the area of staphylococcus
Anti-Infectives Week, July 24, 2006, p. 135

DOCUMENT TYPE: Expanded Reporting
LANGUAGE: English
RECORD TYPE: FULLTEXT
WORD COUNT: 1289

...from the United States report details of new studies and findings in the area of staphylococcus

TEXT:

Staphylococcus data are the focus of recent research from the United States. Study 1: Staphylococcus aureus strains that cause community-acquired methicillin-resistant infections are phenotypically similar among infected children... According to recent research published in the Pediatric Infectious Disease Journal, "Methicillin-resistant Staphylococcus aureus (MRSA) has recently emerged as a common cause of infection in children in many... in the Pediatric Infectious Disease Journal (Clinical and molecular epidemiology of community-acquired methicillin-resistant Staphylococcus aureus infections among

10601171

children with risk factors for health care-associated infection - 2001-2003.
Pediatr...s Hospital Philadelphia, Division of Infectious Diseases,
Philadelphia, PA 19104, USA.

Study 2: Immunization with Staphylococcus aureus clumping factor B, a major determinant in nasal carriage, reduces nasal colonization in a murine model.

According to recent research published in the journal Infection and Immunity, "Staphylococcus aureus is responsible for a wide range of infections, including soft tissue infections and potentially...for staphylococcal infection. Previous studies with rodent models of nasal colonization have implicated capsule and teichoic acid as staphylococcal surface factors that promote colonization."

"In this study, a mouse model of...lower levels of colonization than control animals exhibited," reported Schaffer and his colleagues. "A QfB monoclonal antibody (mAb) inhibited S. aureus binding to mouse cytokeratin 10. Passive immunization of mice with...scientists concluded.

Schaffer and his coauthors published their study in Infection and Immunity (Immunization with Staphylococcus aureus clumping factor B, a major determinant in nasal carriage, reduces nasal colonization in a...Longwood Avenue, Boston, MA 02115, USA. jean.lee@channing.harvard.edu.

Study 3: Methicillin-resistant Staphylococcus aureus infection in patients with thermal injury is controlled immunologically via anti-MRSA effector cell induction.

"Staphylococcus aureus, especially methicillin-resistant S. aureus (MRSA), is a major cause of sepsis in patients...and colleagues published their study in Clinical and Experimental Immunology (Immunological control of methicillin-resistant Staphylococcus aureus (MRSA) infection in an immunodeficient murine model of thermal injuries. Clin Exp Immunol, 2005...Medicine, 301 University Blvd., Galveston, TX 77555, USA.

Keywords: Galveston, Texas, United States, Methicillin-Resistant Staphylococcus aureus, Thermal Injury, Immunological Control, Murine Model, Effector Cells.

This article was prepared by Anti...

DESCRIP TORS: Antimicrobial Resistance; Bacteriology; Drug Resistance; Effector Cells; Galveston; Immunological Control; Methicillin-Resistant Staphylococcus aureus; Murine Model; Staphyloc; Staphylococcal; Texas; Therapy; Thermal Injury; Treatment; United States; All News
SUBJECT HEADIN G: Staphylococcus

5/3, K/23 (Item 5 from file: 135)
DI ALOC R) File 135: NewsRx Weekly Reports
(c) 2012 NewsRx. All rights reserved.

0000318824 (USE FORMAT 7 OR 9 FOR FULLTEXT)

Researchers from the United States and Switzerland detail new studies and findings in the area of staphylococcus
Immunotherapy Weekly, July 19, 2006, p. 398

DOCUMENT TYPE: Expanded Reporting
LANGUAGE: English
RECORD TYPE: FULLTEXT
WORD COUNT: 1076

... from the United States and Switzerland detail new studies and findings in the area of staphylococcus

TEXT:

Staphylococcus data are the focus of recent research from the United States
Page 20

and Switzerland.

Study 1: Immunization with *Staphylococcus aureus* clumping factor B, a major determinant in nasal carriage, reduces nasal colonization in a... According to recent research published in the journal *Infection and Immunity*, "Staphylococcus aureus is responsible for a wide range of infections, including soft tissue infections and potentially... for staphylococcal infection. Previous studies with rodent models of nasal colonization have implicated capsule and teichoic acid as staphylococcal surface factors that promote colonization."

In this study, a mouse model of... lower levels of colonization than control animals exhibited," reported Schaffer and his colleagues. "A CfB monoclonal antibody (mAb) inhibited *S. aureus* binding to mouse cytochrome 10. Passive immunization of mice with... scientists concluded.

Schaffer and his coauthors published their study in *Infection and Immunity* (Immunization with *Staphylococcus aureus* clumping factor B, a major determinant in nasal carriage, reduces nasal colonization in a... therapy has been shown to be highly effective in a murine model of methicillin-resistant *Staphylococcus aureus* (MRSA) infection.

In a recent study from Switzerland, the "therapeutic activity of ceftibiprole medocarbil... MCs and MBCs of ceftibiprole and vancomycin in Mueller-Hinton broth for strain MRG3 were 1 and 4 and 1 and 2 microg/mL, respectively," reported P. Vaudaux and coauthors at the University Hospital in... and Chemotherapy (Intensive therapy with ceftibiprole medocarbil of experimental foreign-body infection by methicillin-resistant *Staphylococcus aureus*. *Antimicrob Agents Chemother*, 2005;49(9):3789-3793).

For additional information, contact P. Vaudaux... identified in the nasal mucosa of patients with recurrent staphylococcal rhinosinusitis.

"Severe infections due to *Staphylococcus aureus* require prolonged therapy for cure, and relapse may occur even years after the first... Infectious Diseases (Evidence of an intracellular reservoir in the nasal mucosa of patients with recurrent *Staphylococcus aureus* rhinosinusitis. *J Infect Dis*, 2005;192(6):1023-1028).

For additional information, contact P... CH-1211 Geneva, Switzerland.

Keywords: Geneva, Switzerland, Anti-Infectives, Antibiotics, Bacteriology, Infectious Disease, Sinusitis, Staphylococcus aureus, Switzerland; Therapy; Treatment;

This article was prepared by Immunotherapy Weekly editors from staff and other reports. Copyright...

DESCRIPTORS: ... Infectives; Antibiotics; Antimicrobial Resistance; Bacteriology; Drug Development; Drug Resistance; Geneva; Infectious Disease; Pharmaceuticals; Sinusitis; Staphylococcal; Staphylococcus aureus; Switzerland; Therapy; Treatment; Treatment; All News; Professional News
SUBJECT HEADINGS: Staphylococcus

5/3, K/24 (Item 1 from file: 457)

DI ALCO R) File 457: The Lancet

(c) 2012 Elsevier Limited. All rights reserved. All rights reserved.

0000145916

USE FORMAT 7 OR 9 FOR FULL TEXT

Radicalised antimicrobial peptides for infection detection

Lupetti, Antonella; Velling, Mck M; Pauwels, Ernest K J; Nibbering, Peter H
The Lancet Infectious Diseases vol. 3, 4 PP: 223-229 Apr 2003 Document Type:
PERIODICAL; General Information Language: English Record Type: New, Fulltext
Length: 7 Pages
Word Count: 5208
Text:

...patients referred to hospital by their primary-care physician are febrile due to an infection. 1 However, in patients with a serious underlying condition fewer than a half of febrile episodes...

...an infection at an early stage of the disease is critical for a favourable outcome. 1,3,4

Most current laboratory tests used to guide the diagnostic process rely on factors...

...Other agents interact with receptors or domains on infiltrating leucocytes, such as 99mTc-labelled antigranulocyte monoclonal antibodies (or fragments thereof) and 99mTc-labelled chemotactic peptides and interleukins.6 Since antimicrobial peptides...

...html. For the sake of simplicity they can be categorised into three main structural classes: (1) linear peptides adopting an amphipathic alpha-helical structure such as cecropin, magainins, bee mellitin, and human ubiquitin and histatins; (2) peptides with disulphide bridges (1-4) may adopt a loop or a beta-sheet structure. The core of some 3...

...lipopolysaccharide, or proinflammatory cytokines such as tumour necrosis factor (TNF) alpha, interferon gamma, and interleukin 1.

In mammals, antimicrobial peptides and proteins are thought to have an essential role in innate... cathelicidins- link the innate with the acquired immune response.19 As schematically represented in figure 1 and the table, antimicrobial peptides and proteins may mediate an acute inflammatory response by recruiting...

...human beta-defensin-2, 22, 24 facilitates leucocyte diapedesis. In addition, cytokines, such as interleukin 1 and TNFalpha, activate the expression of adhesion molecules on the endothelium and circulating leucocytes, thus...

...negatively charged) surface of microorganisms.9 Microbial membranes expose negatively charged phospholipids-eg, lipopolysaccharide or teichoic acids-on their surface, while mammalian cells segregate into the inner leaflet the lipids with...

...reduction of the negatively charged bacterial surface by esterification of phosphatidylglycerol, the major phospholipid of *Staphylococcus aureus*, or of the teichoic acid polymers.33,34 Also, inactivation of antimicrobial peptides by microbial serine proteases as well...

...cells from a range of 99mTc-labelled human antimicrobial peptides/proteins-eg, human neutrophil peptide 1-3 (HNP 1-3, members of the alpha defensins), 10 ubiquitin (UBI), 11 human lactoferrin (hLF), histatin 5...10, 11 These radiolabelled peptides accumulated rapidly (within the first hour) in the target tissues (1-2% of the injected dose). Since alpha defensins are actively involved in the innate and...

...shown in figure 5.44 In addition, studies using a peptide derived from hLF, hLF 1-11, and a peptide lacking the first three residues (including two cationic amino acids)-ie, hLF...

Cited References:

References

1 van Langevelde P, Joop K, van Loon J, et al. Endotoxin, cytokines, and prolactin in...

...Meller J. The role of nuclear medicine in infection and inflammation. *Lancet Infect Dis* 2001; 1: 326-33.

6 Kariv SM. Recent developments in 99mTc-labelled peptide-based radiopharmaceuticals: an overview...

...PS, Pauwels EK, Calame W Imaging of bacterial infections with

- 99mTc-labeled human neutrophil peptide-1. J Nucl Med 1999; 40: 2073-80.
 11 Welling MM, Lupetti A, Balter HS, et...
 ...42: 788-94.
 12 Jones FS, Simms HS. The bacterial growth inhibitor (lactoferrin) of milk. 1. The preparation in concentrated form. J Exp Med 1930; 51: 327-39.
 13 Hultmark D...
 ...1469-76.
 18 Sharma S, Verma I, Khuller GK. Therapeutic potential of human neutrophil peptide 1 against experimental tuberculosis. Antimicrob Agents Chemother 2001; 45: 639-40.
 19 Yang D, Chertov O...
 ...53.
 23 Zhang L, Yu W, He T, et al. Contribution of human α -defensin 1, 2, and 3 to the anti-HIV-1 activity of CD8 antiviral factor. Science 2002; 298: 995-1000.
 24 Niyonsaba F, Soreya A...
 ...M, Ogawa H, Nagaoka I. Evaluation of the effects of peptide antibiotics human β -defensins-1/-2 and LL-37 on histamine release and prostaglandin D(2) production from mast cells...
 ...peptides. Cell 1998; 95: 189-98.
 33 Peschel A, Jack RW, Otto M, et al. Staphylococcus aureus resistance to human defensins and evasion of neutrophil killing via the novel virulence factor...
 ...M, Jack RW, Kalbacher H, Jung G, Gotz F. Inactivation of the dlt operon in Staphylococcus aureus confers sensitivity to defensins, protegrins and other antimicrobial peptides. J Biol Chem 1999; 274...39 Rao AG, Flood T, Maddox J, Duvalck J. Synthesis and characterization of defensin NP-1. Int J Pept Protein Res 1992; 40: 507-14.
 40 Aurelias A, Mangoni M, Roumestand C, et al. Synthesis and solution structure of the antimicrobial peptide protegrin-1. Eur J Biochem 1996; 237: 575-83.
 41 Maloy WL, Kari UP. Structure-activity studies...

5/3, K/25 (Item 2 from file: 457)
 DI ALCO R) File 457: The Lancet
 (c) 2012 Elsevier Limited. All rights reserved. All rights reserved.

0000142267

USE FORMAT 7 OR 9 FOR FULL TEXT

Role of lipoteichoic acid in infection and inflammation

Ginsburg, Isaac

The Lancet Infectious Diseases vol. 2, 3 PP: 171-179 Mar 2002 Document Type:

PERI CDICAL; General Information Language: English Record Type: New, Fulltext

Length: 9 Pages

Word Count: 9077

Text:

...and organ failure resulting from bacterial infections are end results of multiple synergistic "cross-talks" 1-10 among the bacterial cell-wall components lipopolysaccharide (endotoxin), lipoteichoic acid (LTA), peptidoglycan, and superantigens, and many host-derived agents generated by

activated phagocytes. 1,5,6,9,10 The bacterial agents are mainly released after bacteriolysis induced by lysozyme, cationic bactericidal peptides, phospholipase A₂, elastase, and cathepsins. 1,9-12 or by beta lactam antibiotics. 13 Therefore, it is not surprising that almost none...

...haemagglutinating factor are hardly ever cited nowadays.

LTA consists of a hydrophilic region of a 1-3-phosphodiesterase-linked polymer of ribitol phosphate or glycerophosphate variously substituted in the C2 position...from neutrophils or from plasma, bacteriolysis can take place, causing the release of capsular polysaccharides, teichoic acid, peptidoglycan, and LTA. 7-13 Bacteriolysis of staphylococci induced by cationic peptides from leucocytes 11...
...26 or membrane phospholipids, 16 or specifically, to CD14 or to Toll-like receptors (figure 1). LTA from pneumococci has a binding moiety containing choline and binds to specific choline-binding...

...and invasion, but it can also facilitate direct delivery on target cells of proinflammatory agonists. 1,27 Cell binding and injury can be inhibited by hyperimmune gammaglobulin enriched in antibodies to...

...melanogaster. 33,34 The intracellular domain of Toll receptors resembles that of the mammalian interleukin-1 receptor. Whole Gram positive bacteria, peptidoglycan, and LTA bind to Toll receptor 2 (a glycerophosphatidylinositol...

...B, a transcription factor involved in cytokine generation. 35 By contrast, cells expressing Toll receptor 1 or 4 did not show such binding. Also, macrophages deficient in Toll receptor 4 showed...

...LTA binding to cells by removing surface-associated glycoproteins that mask phospholipid-binding sites (figure 1). 16 These issues need further clarification.

Macrophages also have type I scavenger receptors, 36 glycosylated...a potential to contribute to cell damage and also to the postinfectious sequelae.

LTA from *Staphylococcus aureus* induced release from human dermal fibroblasts of hepatocyte growth factor 46 and also acted in synergy with interleukin-1 alpha and beta to release large amounts of this growth factor by human gingival fibroblasts...

...induced by stratum corneum in neutrophils. 50 LTA also induced expression of macrophage inflammatory protein 1 alpha. 51 These findings suggest that LTA may have a role in the regulation, recruitment...

...highly cytolytic lysophosphatides shown to prime human polymorphonuclear cells for generation of reactive oxygen species. 1 Similarly to lipopolysaccharide, LTA also raised serum concentrations of lipoproteins and cholesterol in rats, but...

...core 18,19 might bind to other sites such as CD14 and Toll. 30,31 LTA, teichoic acid, and peptidoglycan each inhibit proliferation of fibroblasts by a still undefined mechanism 56 and...

...enzymes, as an inducer of nitric oxide and cytokines, as a mitogen for T cells, 1,5,8,9,10,27,59,60 and as a transcription factor. 57 LTA can...bovine serum albumin. 72 Meningeal inflammation in rabbits was induced by intracisternal injection of pneumococcus-derived teichoic acid (a ribitol phosphate polymer of unusual complex structure containing phosphorylcholine) or of peptidoglycan. 59,60 However, degraded teichoic acid lacked such activity. Generation of free cell-wall components in cerebrospinal fluid during infection...

...concentrations, LTA synergises with peptidoglycan to amplify generation

of proinflammatory agonists. 31, 32, 61. Figures 1 and 2 summarise a proposed sequence of events that might occur after the interaction of...

...macrophages, and mononuclear cells, in a CD14-dependent pathway, 75 which can be inhibited by monoclonal antibodies to CD14.

LTA from various sources induced circulatory failure and organ injury in a...

...be attenuated by anti-proteinases as well as by N-acetylcysteine and by additions thiol s. 1 -5, 9, 10, 14, 15

LTA and cytokine generation

A large body of evidence is...

...triggers the generation by mononuclear cells of tumour necrosis factor alpha, interferon gamma, and interleukins 1, 5, 6, and 8, but also the antiinflammatory interleukins 10 and 12. 81-89 The...

...of toxic shock syndrome) and LTA generated synergistic amounts of tumour necrosis factor alpha, interleukin 1, and interferon gamma are important because they implicate LTA in the pathophysiology of poststreptococcal sequelae...

Cited References: References

1 Ginsburg I, Kohen R. Cell damage in inflammatory and infectious sites might involve a coordinated...

...inflammatory agonists the main contributory factors to the pathogenesis of postinfectious sequelae? Inflammation 2001; 25: 1-9.

11 Ginsburg I. Cationic polyelectrolytes: a new look at their possible roles as opsonins...

...Appelmek BJ, Schrijver IA, Groeneveld PH. Antibiotic-induced release of lipoteichoic acid and peptidoglycan from Staphylococcus aureus:

quantitative measurements and biological reactivities. Antimicrob Agents Chemother 1998; 42: 3073-78.

24 Heer...

...RBC by lipopolysaccharides and by the cell-sensitising factor of group A streptococci. Inflammation 1976; 1: 247-60.

30 Dziarski R, Uller AJ, Gupta D. Interaction of CD14 with components of... 46 Baroni A, Perfetto B, Ruocco E, Russano F. Lipoteichoic acid and protein A from Staphylococcus aureus stimulates release of hepatocyte growth factor (HGF) by human dermal fibroblasts. Arch Dermatol Res...

...A, Arakaki R, Ohnishi T, Arakaki N, Dai kuhara Y, Takada H. Lipoteichoic acid and interleukin-1 stimulate synergistically production of hepatocytes growth factor (scatter factor) in human gingival fibroblasts in culture...

...JM Struere RM, Kunkel SL, Arnberg DA, Van Q'teren GM, Standiford TJ. Macrophage inflammatory protein-1 alpha expression in vivo and in vitro: the role of lipoteichoic acid. Clin Immunol Immunopathol...

...52.

55 Aasjord P, Nyland H, Matre R. The mitogenic properties of lipoteichoic acid from Staphylococcus aureus. Acta Pathol Microbiol Scand 1986; 94: 91-96.

56 Edds EM, Bergamini TM, Brittan...Y, Kasai K, Akimoto K, Thiernemann C. Induction of NO synthesis by lipoteichoic acid from Staphylococcus aureus in J774 macrophages: involvement of a CD14-dependent pathway. Biochem Biophys Res Commun 1997...

...Gross S, Thiernemann C. Induction of nitric oxide and tetrahydrobiopterin synthesis by lipoteichoic acid from Staphylococcus

aureus in vascular smooth muscle cells. J Vasc Res 1998; 35:104-08.

77 Jungl...

...82 Friesenfeld-Ol, Wölpe S, Gracia-Bustos JF, Hoffman MK, Tuomanen E.

Production of interleukin-1 but not tumor necrosis factor by human monocytes stimulated by pneumococcal cell surface components. Infect...

...21.

89 Wang JE, Jorgense PF, Almfoti M et al. Peptidoglycan and lipoteichoic acid from Staphylococcus aureus induce tumor-necrosis factor alpha, interleukin 6 (IL-6), and IL-10 production in...

? e au=schuman, richard

Ref	Items	Index-term
E1	1	AU=SCHUMAN, REBECCA
E2	2	AU=SCHUMAN, RF
E3	6	*AU=SCHUMAN, RI CHARD
E4	1	AU=SCHUMAN, RI CHARD C.
E5	6	AU=SCHUMAN, RI CHARD F
E6	17	AU=SCHUMAN, RI CHARD F.
E7	1	AU=SCHUMAN, RI CHARD FARREL
E8	1	AU=SCHUMAN, RI CHARD M
E9	3	AU=SCHUMAN, RI CK
E10	1	AU=SCHUMAN, ROBERT
E11	1	AU=SCHUMAN, ROBERT A.
E12	1	AU=SCHUMAN, ROBERT P
E13	15	AU=SCHUMAN, ROBERT P.
E14	1	AU=SCHUMAN, ROSEMARY
E15	1	AU=SCHUMAN, ROSLYN L.
E16	5	AU=SCHUMAN, S
E17	28	AU=SCHUMAN, S.
E18	1	AU=SCHUMAN, S. A.
E19	1	AU=SCHUMAN, S. C.
E20	38	AU=SCHUMAN, S. H.
E21	2	AU=SCHUMAN, S. P.
E22	16	AU=SCHUMAN, S. T.
E23	1	AU=SCHUMAN, S. A.
E24	1	AU=SCHUMAN, S. C
E25	36	AU=SCHUMAN, S. C.

Enter P or PAGE for more

? s e1-e25

1	AU=SCHUMAN, REBECCA
2	AU=SCHUMAN, RF
6	AU=SCHUMAN, RI CHARD
1	AU=SCHUMAN, RI CHARD C.
6	AU=SCHUMAN, RI CHARD F
17	AU=SCHUMAN, RI CHARD F.
1	AU=SCHUMAN, RI CHARD FARREL
1	AU=SCHUMAN, RI CHARD M
3	AU=SCHUMAN, RI CK
1	AU=SCHUMAN, ROBERT
1	AU=SCHUMAN, ROBERT A.
1	AU=SCHUMAN, ROBERT P
15	AU=SCHUMAN, ROBERT P.
1	AU=SCHUMAN, ROSEMARY
1	AU=SCHUMAN, ROSLYN L.

10601171

5 AU=SCHUMAN, S
28 AU=SCHUMAN, S.
1 AU=SCHUMAN, S.
1 AU=SCHUMAN, S. A.
38 AU=SCHUMAN, S. C.
2 AU=SCHUMAN, S. H.
16 AU=SCHUMAN, S. P.
1 AU=SCHUMAN, S. T.
1 AU=SCHUMAN, S. A.
1 AU=SCHUMAN, S. C.
36 AU=SCHUMAN, S. C.
S6 187 E1-E25

? s s6 and staphylococcus

187 S6
933353 STAPHYLOCOCCUS
S7 9 S6 AND STAPHYLOCOCCUS

? rd

S8 6 RD (unique items)

? t s8/3, k/1-6

>>> KWC option is not available in file(s): 399

Dialog eLink:

8/3, K/1 (Item 1 from file: 24)

DIALOG(R) File 24: CSA Life Sciences Abstracts

(c) 2012 CSA. All rights reserved.

0003697420 IP Accession No: 9200024

Safety and pharmacokinetics of a chimerized anti-lipoteichoic acid monoclonal antibody in healthy adults

Weisman, Leonard E; Fischer, Gerald W; Thackray, Helen M; Johnson, Karen E; Schuman, Richard F; Mandy, George T; Stratton, Beth E; Adams, Karen M; Kramer, William G; Mond, James J Department of Pediatrics, Baylor College of Medicine, Houston, TX, United States, [mailto:lweisman@bcm.edu]

International Immunopharmacology, v 9, n 5, p 639-644, May 2009

Publication Date: 2009

Publisher: Elsevier Science, P.O. Box 211 Amsterdam 1000 AE Netherlands,

[mailto:nlinfo-f@elsevier.nl], [URL: http://www.elsevier.nl/]

Document Type: Journal Article

Record Type: Abstract

Language: English

Summary Language: English

ISSN: 1567-5769

File Segment: Immunology Abstracts

Weisman, Leonard E; Fischer, Gerald W; Thackray, Helen M; Johnson, Karen E; Schuman, Richard F; Mandy, George T; Stratton, Beth E; Adams, Karen M; Kramer, William G; Mond...

Abstract:

...against lipoteichoic acid (LTA) and protective in animal models for coagulase-negative staphylococci (CONS) and Staphylococcus aureus bacteremia, was developed for prevention of staphylococcal infection in high-risk populations. This

10601171

open... was approximately 33 days. Opsonophagocytic activity of serum samples on a human clinical isolate of Staphylococcus epidermidis in a standard bacterial killing assay was dose-related, and peaked at a mean...

Descriptors: ... Drugs; Immunoglobulin G; Infection; Intravenous administration; Lipoteichoic acid; Monoclonal antibodies; Pharmacokinetics; Risk groups; Statistical analysis; Staphylococcus aureus; Staphylococcus epidermidis
Identifiers:

Dialog eLink:

8/3, K/2 (Item 2 from file: 24)

DIALOG(R) File 24: CSA Life Sciences Abstracts

(c) 2012 CSA. All rights reserved.

0002984916 IP Accession No: 7128402

Identification of Antigenic Components of Staphylococcus epidermidis Expressed during Human Infection

Pourmand, Mohammad R; Clarke, Simon R; Schuman, Richard F; Mond, James J; Foster, Simon J Department of Molecular Biology & Biotechnology, University of Sheffield, Firth Court, Western Bank, Sheffield, S10 2TN, United Kingdom Biosynex Inc., 9119 Gaither Road, Gaithersburg, Maryland 20877

Infection and Immunity, v 74, n 8, p 4644-4654, August 2006

Publication Date: 2006

Publisher: American Society for Microbiology, 1752 N Street N.W. Washington, DC 20036 USA, [URL: <http://www.asm.org/>]

Document Type: Journal Article

Record Type: Abstract

Language: English

Summary Language: English

ISSN: 0019-9567

Electronic Issn: 1098-5522

File Segment: Immunology Abstracts; Bacteriology Abstracts (Microbiology B)

Identification of Antigenic Components of Staphylococcus epidermidis Expressed during Human Infection

Pourmand, Mohammad R; Clarke, Simon R; Schuman, Richard F; Mond, James J; Foster, Simon J

Abstract:

A spectrum of in vivo-expressed Staphylococcus epidermidis antigens was identified by probing a bacteriophage lambda library of S. epidermidis genomic DNA...

Descriptors: ... Immune response; Immunoglobulin G; Immunotherapy; Infection; Lipase; Opsonization; Phages; Prophylaxis; Scab; Triacylglycerol lipase; Vaccination; genomes; Staphylococcus epidermidis

Identifiers:

Dialog eLink:

8/3, K/3 (Item 1 from file: 399)

DIALOG(R) File 399: CA SEARCH(R)

(c) 2012 American Chemical Society. All rights reserved.

Page 28

140058441 CA: 140(5)58441v PATENT
 Oposonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria for diagnosis and treatment of infection
 Inventor (Author): Stinson, Jeffrey R.; Schuman, Richard F.; Mond, James J.; Lees, Andrew; Fischer, Gerald Walter
 Location: USA
 Patent: U.S. Pat. Appl. Publ.: US 20030235578 A1 Date: 20031225
 Application: US 323927 (20021220) *US 97055 (19980615) *US PV343503 (20011221)
 Pages: 42 pp., Cont.-in-part of U.S. 6,610,293.
 CODEN: USXXOO
 Language: English
 Patent Classifications:
 Class: 424130100; A61K-039/395A; C07K-016/18B

Dialog eLink:
 8/3, K/4 (Item 2 from file: 399)
 DIALOG(R) File 399: CA SEARCH(R)
 (c) 2012 American Chemical Society. All rights reserved.

139116277 CA: 139(8)116277p PATENT
 Oposonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria
 Inventor (Author): Stinson, Jeffrey R.; Schuman, Richard F.; Mond, James J.; Lees, Andrew; Fischer, Gerald Walter
 Location: USA
 Assignee: Biosynexus Incorporated
 Patent: PCT International: WO 200359260 A2 Date: 20030724
 Application: WO 2002US41033 (20021223) *US PV343503 (20011221)
 Pages: 99 pp.
 CODEN: PIXXD2
 Language: English
 Patent Classifications:
 Class: A61K-000/A
 Designated Countries: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW AM; AZ; BY; KG; KZ; MD; RU; TJ; TM
 Designated Regional: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

Dialog eLink:
 8/3, K/5 (Item 3 from file: 399)
 DIALOG(R) File 399: CA SEARCH(R)
 (c) 2012 American Chemical Society. All rights reserved.

139116276 CA: 139(8)116276n PATENT
 Monoclonal antibodies directed to peptidoglycan of Gram positive bacteria
 Page 29

10601171

Inventor (Author): Schuman, Richard F.; Kokai-Kun, John F.; Foster, Simon; Stinson, Jeffrey R.; Fischer, Gerald W

Location: USA

Assignee: Biosynexus Incorporated

Patent: PCT International ; WO 200359259 A2 Date: 20030724

Application: WO 2002US41032 (20021223) *US PV343444 (20011221) *US PV341806 (20011221)

Pages: 102 pp.

CODEN: PIXXD2

Language: English

Patent Classifications:

Class: A61K-000/A

Designated Countries: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH; GM; GR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MY; NZ; OM; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW AM; AZ; BY; BG; BR; BT; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; SI; SK; SL; TM; Designated Regional: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; SI; SK; SL; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

Dialog eLink:

8/3, K/6 (Item 4 from file: 399)

DIALOG(R) File 399: CA SEARCH(R)

(c) 2012 American Chemical Society. All rights reserved.

130080349 CA: 130(7)80349m

PATENT

Oposonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria

Inventor (Author): Fischer, Gerald W; Schuman, Richard F.; Wong, Hing; Stinson, Jeffrey L

Location: USA

Assignee: Henry M Jackson Foundation for the Advancement of Military Medicine

Patent: PCT International ; WO 9857994 A2 Date: 19981223

Application: WO 98US12402 (19980616) *US 49871 (19970616)

Pages: 150 pp.

CODEN: PIXXD2

Language: English

Patent Classifications:

Class: C07K-016/00A

Designated Countries: AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA; CH; CN; CU; CZ; DE; DK; EE; ES; FI; GB; GE; GH; GM; GW; HU; ID; IL; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MD; MG; MK; MN; MW; MX; NY; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; UA; UG; UZ; VN; YU; ZW AM; AZ; BY; BG; BR; BT; CA; CH; CN; CO; CR; CU; CZ; DE; DK; EE; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; ML; MR; NE; SN; TD; TG

? e au=wong, hing

Ref	Items	Index-term
E1	12	AU=WONG, HING-YONG
E2	1	AU=WONG, HING-YONG

```

E3      26 *AU=WONG, HI NG
E4      31 AU=WONG, HI NG C
E5      76 AU=WONG, HI NG C.
E6       3 AU=WONG, HI NG C*
E7       9 AU=WONG, HI NG CHEUNG
E8       1 AU=WONG, HI NG KA
E9       1 AU=WONG, HI NG KWOK
E10     10 AU=WONG, HI NG LOK
E11      3 AU=WONG, HI NG NAM I VY
E12      2 AU=WONG, HI NG S
E13      1 AU=WONG, HI NG S.
E14      2 AU=WONG, HI NG VAN
E15      1 AU=WONG, HI NG C.
E16     16 AU=WONG, HI NG CHEUNG
E17      9 AU=WONG, HI NG I P
E18      1 AU=WONG, HI NG LOK
E19      2 AU=WONG, HI NG VAN
E20      1 AU=WONG, HI NGYUEN DOM NI C
E21      1 AU=WONG, HI NKMND
E22      9 AU=WONG, HI U LAM
E23      1 AU=WONG, HI U LEI
E24      4 AU=WONG, HI U LI NG BEATRI CE
E25      5 AU=WONG, HI U MAN

```

Enter P or PAGE for more
 ? s e1-e25

```

12 AU=WONG, HI N- YONG
1 AU=WONG, HI N- YOUNG
26 AU=WONG, HI NG
31 AU=WONG, HI NG C
76 AU=WONG, HI NG C.
3 AU=WONG, HI NG C*
9 AU=WONG, HI NG CHEUNG
1 AU=WONG, HI NG KA
1 AU=WONG, HI NG KWOK
10 AU=WONG, HI NG LOK
3 AU=WONG, HI NG NAM I VY
2 AU=WONG, HI NG S
1 AU=WONG, HI NG S.
2 AU=WONG, HI NG VAN
1 AU=WONG, HI NG C.
16 AU=WONG, HI NG CHEUNG
9 AU=WONG, HI NG I P
1 AU=WONG, HI NG LOK
2 AU=WONG, HI NG VAN
1 AU=WONG, HI NGYUEN DOM NI C
1 AU=WONG, HI NKMND
9 AU=WONG, HI U LAM
1 AU=WONG, HI U LEI
4 AU=WONG, HI U LI NG BEATRI CE
5 AU=WONG, HI U MAN

```

S9 228 E1- E25

? s s9 and staphylococcus and monoclonal

```

228 S9
933353 STAPHYLOCOCCUS
1716994 MONOCLONAL
S10 1 S9 AND STAPHYLOCOCCUS AND MONOCLONAL

```

? t s10/3, k/1

>>> KWC option is not available in file(s): 399

Dialo g eLink:

10/3, k/1 (Item 1 from file: 399)

DIALOG R) File 399: CA SEARCH(R)

(c) 2012 American Chemical Society. All rights reserved.

130080349 CA: 130(7)80349m

PATENT

Opioid and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria

Inventor (Author): Fischer, Gerald W.; Schuman, Richard F.; Wong, Hing; Stinson, Jeffrey L.

Location: USA

Assignee: Henry M Jackson Foundation for the Advancement of Military Medicine

Patent: PCT International ; WO 9857994 A2 Date: 19981223

Application: WO 98US12402 (19980616) *US 49871 (19970616)

Pages: 150 pp.

OCEN: P1XXD2

Language: English

Patent Classifications:

Class: C07K-016/00A

Designated Countries: AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA; CH; CN; CU; CZ;

DE; DK; EE; ES; FI; GB; GE; GH; GM; GW; HU; ID; IL; IS; JP; KE; KG; KP; KR; KZ; LC;

LK; LR; LS; LT; LU; LV; MD; MG; MK; MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG;

SI; SK; SL; TJ; TM; TR; TT; UA; UG; UZ; VN; YU; ZW AM; AZ; BY; KG; KZ; MD; RU; TJ;

TM

Designated Regional: GH; GM; KE; LS; MW; SD; SZ; UG; ZW AT; BE; CH; CY; DE; DK; ES;

FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; ML; MR;

NE; SN; TD; TG

? e au=stinson, jeffrey

Ref	Items	Index-term
E1	1	AU=STI NSON, JC
E2	4	AU=STI NSON, JE
E3	8	*AU=STI NSON, JEFFREY
E4	4	AU=STI NSON, JEFFREY A
E5	7	AU=STI NSON, JEFFREY A
E6	2	AU=STI NSON, JEFFREY ALAN
E7	3	AU=STI NSON, JEFFREY L.
E8	3	AU=STI NSON, JEFFREY R
E9	10	AU=STI NSON, JEFFREY R
E10	1	AU=STI NSON, JEFFREY RI CHARD
E11	1	AU=STI NSON, JEFFREY S.
E12	10	AU=STI NSON, JELLYN
E13	1	AU=STI NSON, JELLYN A
E14	1	AU=STI NSON, JENNI FER
E15	1	AU=STI NSON, JENNI FER KI RSTEN
E16	1	AU=STI NSON, JENNI FER N.
E17	2	AU=STI NSON, JENNI FER NAN
E18	25	AU=STI NSON, JEREMY
E19	1	AU=STI NSON, JEREMY A
E20	1	AU=STI NSON, JEREMY E.
E21	2	AU=STI NSON, JESSE
E22	1	AU=STI NSON, JILL DI ANE

10601171

E23 194 AU=STI NSON, JIM
E24 1 AU=STI NSON, JIMMY LEON
E25 1 AU=STI NSON, JL

Enter P or PAGE for more
? s e1-e25

1 AU=STI NSON, JC
4 AU=STI NSON, JE
8 AU=STI NSON, JEFFREY
4 AU=STI NSON, JEFFREY A
7 AU=STI NSON, JEFFREY A.
2 AU=STI NSON, JEFFREY ALAN
3 AU=STI NSON, JEFFREY L.
3 AU=STI NSON, JEFFREY R
10 AU=STI NSON, JEFFREY R
1 AU=STI NSON, JEFFREY RI CHARD
1 AU=STI NSON, JEFFREY S.
10 AU=STI NSON, JELYNN
1 AU=STI NSON, JELYNN A.
1 AU=STI NSON, JENNI FER
1 AU=STI NSON, JENNI FER KI RSTEN
1 AU=STI NSON, JENNI FER N.
2 AU=STI NSON, JENNI FER NAN
25 AU=STI NSON, JEREMY
1 AU=STI NSON, JEREMY A.
1 AU=STI NSON, JEREMY E.
2 AU=STI NSON, JESSE
1 AU=STI NSON, JILL DIANE
194 AU=STI NSON, JIM
1 AU=STI NSON, JIMMY LEON
1 AU=STI NSON, JL
S11 286 E1-E25

? s s11 and staphylococcus

286 S11
933353 STAPHYLOCOCCUS
S12 7 S11 AND STAPHYLOCOCCUS

? rd

S13 7 RD (unique items)

? t s13/3, k/1-7

>>> KWC option is not available in file(s): 399

Dial o g eLink:

13/3, k/1 (Item 1 from file: 399)

DI ALCO G File 399: CA SEARCH(R)

(c) 2012 American Chemical Society. All rights reserved.

148470068

CA: 148(21)470068a

PATENT

Use of Staphylococcus simulans lysostaphin variants with reduced immunogenicity in prophylaxis and treatment of Staphylococcal infections

Page 33

10601171

Inventor (Author): Stinson, Jeffrey Richard; Grinberg, Luba; Mond, James

Location: USA

Assignee: Biosynexus Incorporated

Patent: U.S. Pat. Appl. Publ.: US 20080095756 A1 Date: 20080424

Application: US 2007850150 (20070905) *US 2006PV842402 (20060905)

Pages: 43pp

CODEN: USXXOO

Language: English

Patent Classifications:

Class: 424094630

IPC Class: B + Level Value Position Status Version Action Source Office:

A61K-0038/48 A I F B 20060101 20080424 H US

A61P-0031/04 A I L B 20060101 20080424 H US

G12N-0009/52 A I L B 20060101 20080424 H US

Dialog eLink:

13/3, K/2 (Item 2 from file: 399)

DIALOG File 399: CA SEARCH(R)

(c) 2012 American Chemical Society. All rights reserved.

140058441

CA: 140(5)58441v

PATENT

Optimistic monoclonal and chimeric antibodies specific to lipoteichoic acid of Gram positive bacteria for diagnosis and treatment of infection

Inventor (Author): Stinson, Jeffrey R.; Schuman, Richard F.; Mond, James J.; Lees, Andrew; Fischer, Gerald Walter

Location: USA

Patent: U.S. Pat. Appl. Publ.: US 20030235578 A1 Date: 20031225

Application: US 323927 (20021220) *US 97055 (19980615) *US PV343503 (20011221)

Pages: 42 pp., Cont.-in-part of U.S. 6,610,293.

CODEN: USXXOO

Language: English

Patent Classifications:

Class: 424130100; A61K-039/395A; C07K-016/18B

Dialog eLink:

13/3, K/3 (Item 3 from file: 399)

DIALOG File 399: CA SEARCH(R)

(c) 2012 American Chemical Society. All rights reserved.

139302977

CA: 139(20)302977s

PATENT

Truncated lysostaphin with enhanced staphylolytic activity and its production with transgenic microorganisms

Inventor (Author): Stinson, Jeffrey R.; Grinberg, Lioubov; Lees, Andrew; Mond, James J.; Kokai-Kun, John F.

Location: USA

Assignee: Biosynexus Incorporated

Patent: PCT International: WO 200382184 A2 Date: 20031009

Application: WO 2002US40924 (20021223) *US PV341804 (20011221)

Pages: 72 pp

CODEN: PIXXO2

Language: English

Patent Classifications:

Class: A61K-000/A

Designated Countries: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MY; NZ; OM; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; Designated Regional: CH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

Dialog eLink:

13/3, K/4 (Item 4 from file: 399)

DIALCO (R) File 399: CA SEARCH (R)

(c) 2012 American Chemical Society. All rights reserved.

139163590 CA: 139(11)163590v

PATENT

Intranasal application of monoclonal antibodies for blocking or alleviating staphylococcal nasal colonization

Inventor (Author): Kokai-Kun, John F.; Mond, James J.; Fischer, Gerald W.; Stinson, Jeffrey R.; Walsh, Scott M.; Lees, Andrew

Location: USA

Assignee: Biosynexus Incorporated

Patent: PCT International : WO 200363772 A2 Date: 20030807

Application: WO 2002US40925 (20021223) *US PV341806 (20011221)

Pages: 74 pp.

CODEN: PXXXX2

Language: English

Patent Classifications:

Class: A61K-000/A

Designated Countries: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MY; NZ; OM; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; Designated Regional: CH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

Dialog eLink:

13/3, K/5 (Item 5 from file: 399)

DIALCO (R) File 399: CA SEARCH (R)

(c) 2012 American Chemical Society. All rights reserved.

139116277 CA: 139(8)116277p

PATENT

Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram-positive bacteria

Inventor (Author): Stinson, Jeffrey R.; Schuman, Richard F.; Mond, James J.; Lees, Andrew; Fischer, Gerald Walter

Location: USA

Assignee: Biosynexus Incorporated

10601171

Patent: PCT International ; WO 200359260 A2 Date: 20030724

Application: WO 2002US41033 (20021223) *US PV343503 (20011221)

Pages: 99 pp.

CODEN: PI XXD2

Language: English

Patent Classifications:

Class: A61K-000/A

Designated Countries: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; Designated Regional: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

Dialog eLink:

13/3, R/6 (Item 6 from file: 399)

DIALOG R/6 File 399: CA SEARCH(R)

(c) 2012 American Chemical Society. All rights reserved.

139116276 CA: 139(8)116276n PATENT

Monoclonal antibodies directed to peptidoglycan of Gram-positive bacteria

Inventor (Author): Schuman, Richard F.; Kokai-Kun, John F.; Foster, Simon; Stinson, Jeffrey R.; Fischer, Gerald W

Location: USA

Assignee: Biosynexus Incorporated

Patent: PCT International ; WO 200359259 A2 Date: 20030724

Application: WO 2002US41032 (20021223) *US PV343444 (20011221) *US PV341806 (20011221)

Pages: 102 pp.

CODEN: PI XXD2

Language: English

Patent Classifications:

Class: A61K-000/A

Designated Countries: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; Designated Regional: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

Dialog eLink:

13/3, R/7 (Item 7 from file: 399)

DIALOG R/7 File 399: CA SEARCH(R)

(c) 2012 American Chemical Society. All rights reserved.

130080349 CA: 130(7)80349m PATENT

Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid

10601171

acid of gram positive bacteria

Inventor (Author): Fischer, Gerald W.; Schuman, Richard F.; Wong, Hing; Stinson, Jeffrey L.

Location: USA

Assignee: Henry M. Jackson Foundation for the Advancement of Military Medicine

Patent: PCT International ; WO 9857994 A2 Date: 19981223

Application: WO 98US12402 (19980616) *US 49871 (19970616)

Pages: 150 pp.

CODEN: PIXXD2

Language: English

Patent Classifications:

Class: C07K-016/00A

Designated Countries: AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA; CH; CN; CU; CZ;

DE; DK; EE; ES; FI; GB; GE; GH; GM; GW; HU; ID; IL; IS; JP; KE; KG; KP; KR; KZ; LC;

LK; LR; LS; LT; LU; LV; MD; MG; MK; MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG;

SI; SK; SL; TJ; TM; TR; TT; UA; UG; UZ; VN; YU; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ;

TM

Designated Regional: GH; GM; KE; LS; MW; SD; SZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES;

FI; FR; GB; GE; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; ML; MR;

NE; SN; TD; TG

? ds

Set	Items	Description
S1	680	E1-E25
S2	287001	1 AND STAPHYLOCOCCUS
S3	4365	S2 AND MONOCLONAL
S4	45	S3 AND TEI CHOIC
S5	25	FD (unique items)
S6	187	E1-E25
S7	9	S6 AND STAPHYLOCOCCUS
S8	6	FD (unique items)
S9	228	E1-E25
S10	1	S9 AND STAPHYLOCOCCUS AND MONOCLONAL
S11	286	E1-E25
S12	7	S11 AND STAPHYLOCOCCUS
S13	7	FD (unique items)